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 Viral proteins are a potential candidate for subunit vaccine development as they are able 
to self-assemble into an authentic structure without the existence of an infectious genome. 
However, its poor immunogenicity limits its applications for vaccine delivery. Therefore, this 
work aims to develop an antigen-adjuvant complex to increase the immune response and cell 
viability with viral proteins, as well as investigate the mechanism of inflammasome signaling 
with the antigen-adjuvant complex in vitro. 
Simian Virus 40 viral protein 1 (SV40 VP1) viral protein with a size of ~20 nm in 
diameter was produced as a recombinant protein using a baculovirus expression vector system, 
and verified using SDS-Page and Western Blot analysis. SV40 VP1 was then successfully 
encapsulated onto sacrificial CaCO3 microparticles using layer-by-layer deposition of 
biodegradable dextran/poly-L-arginine polyelectrolyte pairs. Zeta potential measurements, 
energy-dispersive spectroscopy, scanning electron and transmission electron microscopy 
confirmed the successful fabrication of the viral protein based polymeric multilayer capsule (VP-
PMLC). Two approaches of viral protein encapsulation and different molecular weights (MW) of 
polyelectrolytes were investigated, and the highest encapsulation efficiency of 63% was 
observed using high MW polyelectrolyte pairs with protein deposited in the first layer. 
In vitro release profiles were investigated with DC2.4 dendritic cells using fluorescent 
labeled dextran and 20nm fluorescent labeled silica beads to mimic the size of SV40 VP1. 
Confocal microscopy demonstrated that all particles were engulfed within 4h, and while leakage 





fabrication with high MW of polyelectrolytes did not result in leakage of silica beads until 48h to 
72h. 
The overall cell viability was ~ 80% with a particle/cell ratio of ~20. The expression of 
co-stimulatory molecules, CD40 and CD86, was used to evaluate immune response with the 
antigen and adjuvant. It was observed that VP-PMLCs stimulate higher immune response in 
bone marrow-derived dendritic cells (BMDCs). An examination of the secreted cytokine profile 
from exposed BMDC cultures showed significant secretion of the pro-inflammatory cytokine IL-
1β but no detectable increase in the levels of other pro-inflammatory cytokines such as IL-12 and 
TNF-α. We then verified that cathepsin B was required for IL-1β secretion, but the actin 
polymerization was not necessary.  
Together, our results demonstrate that SV40 VP1-based PMLCs are able to elicit stronger 
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Vaccination is the most efficient way to control and prevent diseases. Currently, the most 
effective way is through parenteral immunization with booster doses. The inconvenience and 
patient noncompliance creates the need for more efficient vaccine fabrication strategies. Taken 
together, recent attention has been given to subunit vaccine, composed by part of pathogens.  
Viral protein can assemble spontaneously through one or more viral protein units without 
the existence of viral genome and have properties similar to the responding virions [1]. This 
authentic structure provides the ability to mimic viral attachment and virion assembly, resulting 
in the capability of cellular and humoral immune responses for both viral and non-viral 
diseases[2]. Taking advantage of the versatile modification and safety approach, recombinant 
proteins are usually evaluated as a potential vaccine candidate. However, the viral protein alone 
serving as antigen showed lower immunogenicity by poorly presented to the immune systems, 
and the help from adjuvants are needed.  
The toxicity and the failure to induce potent CD4 Type 1 T helper cells and CD8 
cytotoxic T cell responses [3] present a problem for the conventional adjuvants. Biodegradable 
polyelectrolytes further show a potential candidate due to its variety. The existence of the 
polyelectrolytes may also slow the viral protein release profile, which resulted in enhancing the 
dendritic cell-binding probability and inducing stronger immune stimulation. 
Therefore, by assembling viral protein onto biodegradable polyelectrolytes, this work 





of viral protein-based capsules. The cytotoxicity, release profile, immune response, cytokines 
and inflammasome signaling pathway towards mice dendritic cells in vitro are studied as well. 
1.2 Specific aims and basic hypothesis 
1.2.1 Fabrication and characterization of viral protein encapsula ted polymeric 
multilayer capsule (VP-PMLC) 
 Recombinant viral protein encapsulated by polyelectrolytes is first fabricated in this research.  
The Simian Virus 40 viral protein 1 is harvested by a baculovirus expression vector 
system. The biodegradable polyelectrolytes, Dextran and Poly-L-Arginine, are applied as 
polyanion and polycation, respectively. Through Layer-by-Layer technology, the viral protein 
fabrication with polyelectrolyte pairs is done by the electrostatic interactions. ξ-potential  is then 
applied to monitor the surface charge on each layer, scanning electron microscopy; energy 
dispersive spectroscopy and transmission electron microscopy images gives evidences for the 
capsule morphology and the successful of the fabrication; confocal laser scanning microscopy is 
used by applying fluorescent labels towards polyelectrolyte to verify its structure; and viral 
protein encapsulation efficiency is measured by bicinchoninic acid protein assay kits 
1.2.2 In vitro immunity study on mice bone marrow derived dendritic cells  
Dendritic cells are immune cells that effectively link the innate and adaptive arms of the 
immune systems. They are considered a professional antigen-presenting cell population not only 
due to their ability to stimulate 100 to 3000 T cells but also because of their unique capacity to 
induce the activation and differentiation of naive T lymphocytes. As for particulate immune 
systems, dendritic cells showed the ability to take up more particles than macrophages [4]. 
Therefore, here we aim to investigate the in vitro properties of co-culturing viral protein-based 





Several viral protein-based polymeric multilayer capsules are tested by either 
encapsulation through different molecular weight of polyelectrolytes or different approaches of 
viral protein encapsulation. The in vitro studies include 1) cell viability through lactate 
dehydrogenase cytotoxicity assay kits, 2) release profile through confocal laser scanning 
microscopy with fluorescent dextran and silica beads, and 3) surface immune level through 
surface markers, CD40 and CD86, by flow cytometry analysis on mice bone marrow derived 
dendritic cells. 
1.2.3 In vitro signal pathway study on mice bone marrow derived dendritic cells  
Cytokines are another crucial factor for immune response especially on the ability to 
activate adaptive immune systems. TNF-α, IL-12 and IL-1β are detected by mice bone marrow 
derived dendritic cells co-cultured with these viral protein-based polymeric multilayer capsules. 
The secretion level is then measured by ELISA assay kits. With positive cytokine secretion 
observed, in vitro inflammasome signaling pathway is then investigated.   





2. LITERATURE REVIEW 
 
The immune system is composed of special cells, proteins, tissues and organs to defend 
the body from attacks by microorganisms and pathogens. In order to function properly, the 
immune systems must be able to detect a wide range of pathogens and also distinguish between 
them and healthy tissue [5].  
Vaccines, which are made of dead or weakened antigens, are the most efficient way to 
train the immune system. The amount of these antigens is not enough to cause an infection, but is 
still sufficient to induce innate immunity, which further activates adaptive immune responses to 
produce antibodies. After the threat has been cleared, many of the antibodies will be cleared 
from the body but this memory remains in immune cells. When the body encounters the specific 
antigen again, the memory cells produce antibodies quickly and eliminates the pathogen [6].  
The most effective vaccines currently are attenuated vaccines based on parenteral 
delivery. Though these living vectors are able to activate innate immune systems and further 
develop robust memorized antibodies, the safety issues are still a concern. Therefore, vaccine 
design has shifted from containing the whole microorganism to only part of it.  
2.1 Viral protein-based subunit vaccines 
Vaccination is the most efficient way to control and prevent infections. The first vaccine 
was created in 1796 by Edward Jenner, the father of immunology, and successfully eradicated 
smallpox and demonstrated the power of the vaccine. Vaccines are generally classified as 
inactivated, live attenuated and subunit vaccines [7-9]. Inactivated vaccines, such as Polio 
vaccine and Hepatitis A vaccine, are made using dead pathogens. These microbes are killed by 





Live attenuated vaccines, such as Measles vaccine, Mumps vaccine, Rubella vaccine and Nasal-
Spray Flu vaccine, contain a microbe variant that has been weakened in the lab. These vaccines 
are efficient and less toxic than live pathogens, but they are still able to replicate inside the 
human body [11, 12]. Subunit vaccines do not introduce pathogens that can replicate in the body, 
and are the focus of current research as they are safe and represent an effective approach for 
vaccine development [13]. Influenza vaccine and Hepatitis B vaccine are two vaccines that 
belong to this sub-category of vaccines.  
Subunit vaccines are composed only by the antigenic parts of the pathogen, which are 
necessary to elicit a protective immune response, such as viral capsid protein antigens [14]. Viral 
capsid protein antigens are part of the virus which self-assemble into higher-order three-
dimensional architectures and preserve the antigenic structure of virus immunogenes. Therefore, 
they are capable of invading and entering cells but do not lead to infection [1]. However, these 
peptide-based or highly purified protein components do not effectively activate the host innate 
immune response like a natural infection would do [15]. Although subunit vaccines represent a 
safe and effective means of vaccination, highly purified viral protein alone elicits weak induction 
of innate immunity in the host. Therefore, such vaccines require additional components known 
as adjuvant, that increases the level of innate immunity activation and enhances the 
immunogenicity of antigens used in vaccines [16, 17].  
2.1.1 Antigens and adjuvants 
Adjuvants, including inorganic, organic, macromolecules and bacteria, are chemical 
permeation enhancers that have been used to augment the immune response towards antigens by 
immune cells, inducing cytokine expression or activated antigen-presenting cells [3, 18]. They 





immunologically inert. In the context of application to vaccine delivery, adjuvants have several 
advantages as they: (a) activate different signaling pathways [19], (b) serve as a depot barrier 
resulting in slow release [20], (c) minimize the amount of antigens needed [21], and (d) facilitate 
oral delivery[22, 23]. Currently, aluminum salts [24], oil-in-water emulsion MF59 [25], Freund’s 
adjuvants [26], heat-labile enterotoxin [27], cholera enterotoxin [28], lipopolysacchride (LPS) 
[29], chemokine CCL28 [30] and oligodeoxynucleotide containing CpG motifs [31-33] are used 
as adjuvants in vaccine development. However, toxicity of the adjuvants and failure to induce 
potent CD4 Type 1 T helper cells (TH1) and CD8 cytotoxic T cell responses are problems that 
limit the use of conventional adjuvants [3].  
One proposed solution to improving the performance of adjuvants is the use of 
biodegradable and biocompatible polymers, including dextran, caprolactone [34], inulin [35], 
and chitosan [36]. For example, though chitosan has not been confirmed to stimulate an immune 
response, it affects antigen release because of its intrinsic ability to open tight junctions and 
adhere to the mucosal surface [28, 37]. Though the mechanism by which PMLCs induce an 
immune response is still unclear, evidence shows that PMLCs, composed of Poly-L-
Arginine/Dextran polymers (PLARG), play a crucial role in mediating dendritic cell activation in 
vivo [38]. Evidence also shows that PLARG provides strong enhancement of the mucosal specific 
IgA response in vivo [39, 40]. These studies illustrate the advantages of using biodegradable 
polymers as adjuvants.  
With an antigen-polymer complex, the uptake mechanism of antigen-presenting cells 
might be different from that of the antigen itself. The antigen-polymer complex can be 





secretion of the cytokine IL-1β, acts as a ligand for toll-like receptors, or directly interact with B 
cells [3]. 
2.1.2 Viral protein characteristics  
A virus is a small infectious agent that replicates only inside the living cells of other 
organisms. It is composed mainly of nucleic acids surrounded by a protective coat of protein, 
also called as capsid protein [2]. A virus might be composed of several viral proteins, but the 
capsid protein is the only one which is able to form the viral cover without the genome from 
identical protein subunits. Therefore, the viral protein alone is not infectious, is capable of 
delivering viral genomes into targeted cells, and thus is a promising tool for the delivery of 
genes, drugs, and pharmaceuticals [42-44]. 
The most well-known and commercial subunit vaccine is the Hepatitis B vaccine. 
Hepatitis B vaccine was first commercially available in 1982, and composed of Hepatitis B 
surface antigen (HBsAg) purified from the plasma of patients with chronic Hepatitis B virus 
infection [45]. The source of HBsAg has now been replaced with heterologous expression of the 
HBsAg gene using yeast or mammalian cells to eliminate concerns associated with the use of 
human blood products [46]. The HBsAg protein is adsorbed to aluminium hydroxide or 
aluminium phosphate, and is used as the adjuvant for better immunization. While effective, three 
injections are needed to prevent Hepatitis B infection [47]. Therefore, there is significant interest 
in developing subunit vaccines that have the effectiveness of the Hepatitis B vaccine but require 
fewer injections. 
In this work, Simian Virus 40 (SV40) Viral Protein 1, the capsid protein of SV40, is 
chosen as the antigen due to its long-term gene expression in target cells and its capability to 





the SV40 wild-type [48]. SV40 belongs to the Polyomavirus family and was isolated in 1960 as a 
contaminant of human polio vaccines originating from monkey cells harvested during the 1950s 
[49, 50]. SV40, which could abortively infect and transform mice cells in vitro, does not replicate 
in mice cells [51]. However, whether SV40 can cause human tumors has been a highly 
controversial issue for over 50 years. There is inadequate evidence to support widespread SV40 
infection in the human population or a direct role for SV40 in human cancer treatment [52-54]. 
Though SV40 is still under investigation as a human virus, SV40 VP1 virus-like particle is 
considered to be safe for use as a vaccine vehicle [55]. 
 
 







SV40 is a small, non-enveloped, double-strained deoxyribonucleic acid (DNA) virus with 
a diameter of 45 nm and a circular genome of ~ 5 kb, which encodes three viral proteins, viral 
protein 1 (VP1), viral protein 2 (VP2) and viral protein 3 (VP3) [56, 57]. As shown in Figure 1, 
the outer shell contains 360 monomers of the major capsid protein VP1, arranged in 12 
pentavalent and 60 hexavalent pentamers with an isoelectric point (pI) equals to 6.8 [56, 58]. It 
unexpectedly forms three different types of connections in the T = 7d icosahedral surface lattice, 
which is inconsistent with the quasi-equivalent bonding theory [59]. The structure of SV40 VP1 
is a jellyroll β-barrel with extending amino- and carboxy-terminal arms [56]. Each VP1 
monomer forms extensive contacts with its neighbors, VP2 and VP3; the amino-terminal (N-
terminal) arm of VP1 binds DNA and faces the interior of the capsid and the carboxy-terminal 
(C-terminal) arm ties the 72 pentamers together by disulfide bridge. SV40 VP2 and VP3 have the 
same sequences in their C-terminus but differ in their N-terminus composition [56]. The SV40 
genome, ses, presents within the viral regulation region and plays a crucial role for replication 
[60]. 
SV40 VP1 serves as capsid protein is responsible for the attachment to the host cells. The 
journey of a virus traveling from the cell surface to the nucleus contains mainly four distinct 
steps [61]: receptor binding, targeting to the endoplasmic reticulum, endoplasmic reticulum 
membrane penetration and nuclear entry. 
First, SV40 virions bind to the cell surface via the ganglioside and Major 
Histocompatibility Complex (MHC) class I. Because there are 360 binding sites in each SV40, 
the SV40-GM1 interaction is relatively strong. Second, after binding, SV40 virions enter the cell 
by caveolae-mediated endocytosis and travels to the endoplasmic reticulum. Third, in the 





reticulum-associated degradation-mediated cytosol transport or viroporin-mediated nuclear 
entrance. Finally, SV40 can travel through the cytosol to nuclear pores [56, 61, 62].  
As a subunit vaccine, the capsid protein alone can form virus-like particles without the 
needs of viral genome, showing more authentic conformation of viral antigens than other subunit 
vaccines. Besides its structural function, virus-like particles alone possess a receptor-binding 
domain [63], a nuclear localization signal domain, a DNA-binding domain, as well as a calcium-
ion-binding domain [64]. These aspects are crucial in mimicking viral attachment and virion 
assembly, resulting in the ability to stimulate efficient cellular and humoral immune responses 
for both viral and non-viral diseases [2]. Therefore, the SV40 VP1 viral protein was used in this 
work. 
SV40 VP1 is small, non-infectious, and capable of self-assembly [65]. The repeated units 
of SV40 VP1 viral protein and its highly organized structure further facilitates the formation of 
mono-dispersed capsules easily. These capsules can be engineered at their internal, external or 
inter subunit interfaces at specific locations, allowing for highly controlled surface properties 
[66]. Also, several studies have investigated different factors and mechanisms of SV40 VP1 self-
assembly and disassembly, which has led to their use in several applications [48, 67]. The 
mechanism of dissociation and re-assembly of SV40 VP1 viral protein is also well studied [67-
70]. Moreover, SV40 VP1 viral protein can non-specifically target cells, induce non-preexisting 
immune response in humans and provides many binding sites on the viral protein surface [71]. 
These properties make SV40 VP1 an ideal candidate for the development of vehicles for vaccine 
delivery [72]. 
SV40 VP1 virus-like particle was first produced by the Escherichia coli (E. coli) bacterial 





spontaneously, with a size and morphology similar to the wild-type SV40 (wtSV40) [73]. 
However, this system may not be ideal for scale up and lack posttranslational modifications, such 
as phosphorylation, sulfation, methylation, acetylation and hydroxylation, that occur only in 
eukaryotic cells [74]. Therefore, the eukaryotic baculovirus expression vector systems (BEVS) is 
considered to be a better production system for SV40 VP1 as it provides more benefits [75]. 
These advantages include: 1) ability to harvest larger amount of recombinant proteins, 2) having 
correct protein folding because of production in eukaryotic cells, 3) narrow host range for 
infection, 4) can be terminated easily and 5) more amenable to scale-up [76]. Furthermore, it can 
also be potentially used for investigating the transportation to the nucleus and protein-protein 
interactions [77]. Therefore, there are broad applications for virus-like particles. For instance, 
they can be used as a tool for providing the natural structure for studying virus-host interactions, 
investigating the assembly factors between major and minor proteins and performing 
fundamental research about the virus and the vaccines. Though they target cells in a non-specific 
manner, their ability to be easier modified to bind ligands, such as human Epidermal Growth 
Factor [78, 79] or tumor lysate [80], making them a potential candidate for tumor vaccine 
vehicles. 
Nevertheless, most virus-like particles already in use as vaccine vehicles show poor 
activation of immunogenic pathways and need adjuvants for enhancement of immune responses. 
Evidence shows that SV40 VP1 viral protein is presented as a natural adjuvant on cytotoxic T 
lymphocytes (CTL) induction. Therefore, SV40 VP1 viral protein is a promising alternative for 







2.1.3 Polymeric multilayer capsule (PMLC) self-assembly technology 
Several approaches can be used to encapsulate antigens into particulate platforms, such as 
reverse micro-emulsion [81, 82], spray drying [83], and Layer-by-Layer (LbL). Considering 
recent advances in antigen encapsulation through polymers [84], the LbL technique further 
provides a more flexible and variable means to encapsulate antigens. 
The LbL technique, first introduced by Gero Decher in the early 1990s, is based on 
sequential adsorption of oppositely charged polyelectrolytes onto a solid, charged surface via 
electrostatic interactions [85]. It is a well-known, reproducible and versatile technique for 
encapsulating a wide range of particles and makes it easier to control wall thickness, 
composition, physical, chemical surface properties and controlled-release profile [86]. This 
method can be applied in drug encapsulation [86-91], sustained release dosage form [92], gas 
barrier [93] and biosensors, etc. As for vaccine delivery applications, the polyelectrolyte shells 
can further protect antigens for other delivery routes, such as mucosal delivery [23, 94]. 
Originally, LbL was applied on charged planar substrates, such as silicon wafers. The 
LbL procedure can be divided into two steps (Figure 2) [85]. First, the charged planar substrate is 
immersed into an oppositely charged polyelectrolyte solution for a certain time, then removed 
and washed with deionized water to remove excess polyelectrolyte. This causes the 
polyelectrolyte to absorb to the substrate surface and reverses the surface charge of the substrate 
due to electrostatic charge. Second, the substrate is immersed into the second polyelectrolyte 
solution, which has a different charge from the first polyelectrolyte, then removed and washed 
with deionized water (DI water) to remove excess polyelectrolyte. Once again, the second 
polyelectrolyte absorbs to the substrate surface and reverses the surface charge of the substrate. 





thickness, composition or surface function needs. Besides electrostatic interactions, other 
interactions, including hydrogen bonding, hydrophobic interaction, covalent bonding, biospecific 
interactions, stereocomplex formation or van der Waals forces can also be used to absorb 
materials onto the particle surface through LbL build-up [95]. 
 
 




Recently, more applications of LbL are merging in the fields of pharmaceuticals and 
biotechnology, to form forming nano- or microparticulates for use in vaccine delivery and 
controlled-release [89]. LbL has also been extended to colloidal systems, with the encapsulated 
macromolecules including DNA, enzyme [96], proteins [38, 97-99], live E. coli [100], lipids or 
other bioactive materials.  
The procedure to build PMLCs is almost the same as the original LbL approach, but the 
problem is that the macromolecules are too small to be centrifuged down with normal speed. 
Therefore, a sacrificial core, such as calcium carbonate (CaCO3) [98], Cadmium carbonate [101], 
and Manganese carbonate crystals [102], is applied to facilitate centrifugation and removed later 





PMLCs are fabricated in three steps: first, the antigen is encapsulated in the sacrificial 
porous micro-templates; second, these micro-templates are coated with alternating anioic and 
cationic polyelectrolytes until desired properties are reached; finally, the sacrificial core is 
decomposed at relatively mild conditions to form the macromolecule PMLCs [98]. PMLC 
fabrication techniques can be applied to a broad range of polyelectrolytes and biomolecules, such 
as the protein encapsulation [99],  live E. coli encapsulation [100] and enzyme encapsulation 
[96]. Moreover, it can strongly increase antigen delivery towards professional antigen presenting 
cells, such as dendritic cells, macrophages and B cells. The existence of the polyelectrolytes may 
also slow the viral protein release profile which can result in enhancing the dendritic cell 
activation and stronger immune stimulation. 
In this work, calcium carbonate is chosen as the sacrificial core. CaCO3 microparticles 
were fabricated by colloidal crystallization from supersaturated solution, which led to the 
formation of uniform spherical porous microparticles with a narrow size distribution. Variable 
sizes of CaCO3 microparticles can be generated by varying fabrication conditions, such as the 
agitation speed, the agitation time or salt concentration [103]. CaCO3 microparticles were formed 
by directly mixing calcium chloride and sodium carbonate under vigorous stirring and initiated 
by heterogeneous precipitation. After crystals formed, the terminated step was then applied by 
centrifugation and followed by thoroughly washed with DI water. 
A wide variety of materials can be deposited, providing an easier way to control the 
thickness and meet requirements for surface modification. Biodegradable polyelectrolytes are 
currently broadly applied for therapeutic applications, as they can be degraded by cells and 





Poly-L-Arginine (PLARG) as the polycation, which can be enzymatically degraded both in vitro 
[105, 106] and in vivo [107].  
Dextran is a complex, branched glucan composed of chains of variable length [108]. As a 
sodium salt, dextran is a strong negatively charged polymer with a pKa value of 6.4, average 
molecular weight (MW) over 500 kDa, and is soluble and stable in water with a broad range of 
pH values. The chemical structure of dextran is shown in Figure 3a. Due to the repulsion of the 
negatively charged sulfate groups, the DS sulfate polymer is fully extended in low ionic strength 
solutions. On the other hand, PLARG is a cationic poly-amino acid with a pKa value of 12 and 
average MW over 70 kDa, provides durable high positive charges with a broad range of pH 
values and assembles into stable and non-aggregated capsules. The chemical structure of PLARG 
is shown in Figure 3b. PLARG has also been demonstrated to disturb cell membranes and rapidly 
be phagocytozed by dendritic cells. However, PLARG alone does not evoke T cell responses and 
can be used for booster function [109]. 
 
 









In order to increase the uptake by professional antigen-presenting cells, templating of 
antigens in nano- or microparticulate carriers by entrapment into the polymer network has been 
adopted [3, 41]. This is especially true for antigens in the 0.1 to 10 µm size range, which is 
similar to the dimension of pathogens, and shows potential to be recognized by dendritic cells 
[110]. For example, ovalbumin encapsulated by DS/PLARG PMLCs, DS/PLARG 
polyelectrolytes were encapsulated by dendritic cell in vivo with high efficiency and resulted in 
better antigen presentation to CD4+ and CD8+ cells [38]. 
Several factors, such as the thickness, numbers of layers, pH of the medium, surface 
charge, particle size, and surface properties, are important for antigen-polyelectrolyte fabrication 
[111-114]. The thickness of the shell is mainly determined by the property of polyelectrolytes 
and the number of layers we desired [111]. The influence of the surface charge on the outer layer 
of capsule is still unclear. Some studies propose that, particles with positively charged surface 
possessed an inherent adjuvanticity due to the electrostatic interaction with negatively charged 
membrane [112]. However, other studies showed that negatively charged surface, ~-20 mV, 
which show similar surface charge of bacterial and mammalian cells, leads to higher uptake 
behavior by immune cells [113]. As for the size factor, though dendritic cells are known to be 
able to engulf particles ranging from 0.1 to 10 μm in diameter, particle size ranging from 1-3 μm 
display higher uptake efficiency [114]. Moreover, the curvature or the roughness of the particle 
surface is another important factor that needs to be considered. 
Together, several biomacromolecule encapsulated by PLARG/DS capsules provide 
evidence to support that PLARG/DS as adjuvants could strongly increase antigen delivery 
towards professional antigen-presenting cells [38]. However, no studies investigating viral 





2.2 Immune responses 
2.2.1 Immune system 
The two main classes of immunity are innate immunity and adaptive immunity. Innate 
immunity provides an immediate response to pathogens and alerts our bodies while, adaptive 
immunity is able to develop a specific army to eliminate pathogens [5]. 
The innate immune system is also a non-specific system providing immediate defense 
against infection. These cells, such as natural killer cells, mast cells, eosinophils, basophils and 
phagocytic cells, including macrophages, neutrophils, and dendritic cells, circulate in the blood 
and are able to recognize potentially harmful, non-self particles agents such as bacteria, viruses, 
pollen, dust or toxic chemicals. The non-self particles which are infectious and cause an immune 
response are termed as antigens, such as bacteria and viruses. The immune response can be 
induced by the entire non-self particle or by part of it [5]. 
 The adaptive immune system, also called acquired immune systems, is an antigen-
specific immune system. The adaptive immune system is composed of highly specialized cells, 
including B-cells and T-cells, and is aimed to eliminate pathogens or prevent their growth [5]. 
Adaptive immunity provides immunological memory after an initial response to a specific 
pathogen leads to an enhanced and quicker response to subsequent encounters with that pathogen 
[5]. Having antibodies ready in advance before pathogen infection is the primary benefit of 
vaccination; however, lymphocytes, which are able to produce specific antibodies and kill 
pathogens, are not normally circulating in the bloodstream [5]. Therefore, a connector between 
innate and adaptive immune systems is required. 
Dendritic cells were first discovered in 1973 by the Steinman group, and are the initiator 





antigen presenting cells due to their ability to uptake, process and present foreign pathogens 
[116]. They are located in tissues such as the gut, circulate in the bloodstream and can contact 
external environments through the skin, the inner mucosal lining of the nose, lungs, stomach, and 
intestines [117]. Since dendritic cells are located in tissues that are common points for initial 
infection, they can identify threats and act as messengers for the rest of the immune systems by 
antigen presentation. Immature dendritic cells, serve as the first line of defense and circulate 
through the bloodstream [5]. Either directly activated by conserved pathogen molecules or 
indirectly by inflammatory mediators, dendritic cells mature and are able to elicit cytokines to 
recruit and activate adaptive immunity, such as T helper cells, to produce the specific antibody 
and eliminate pathogens.  
In order to activate naïve lymphocytes from innate immunity, three signals are required: 
an antigen signal through the T cell receptor or B cell receptor, a co-stimulatory signal, such as 
CD40, CD86, and a cytokine signal. Once lymphocytes receive these three signals from antigen-
presenting cells, effector T cells, and B cells, they differentiate and are activated [118]. 
Macrophages, dendritic cells, and B cells are the only cell types that can express specialized co-
stimulatory molecules required to activate naïve T-cells [5]. However, differnet cells stimulate T-
cells through different mechanisms. Dendritic cells can take up, process and present antigens 
from all types of sources, are only present in the T-cell areas, and overwhelmingly drive the 
initial clonal expansion and differentiation of naïve T cells into effector T-cells. However, 
macrophages and B cells specialize in processing and presenting antigens from intracellular 





Immature dendritic cells migrate through the bloodstream to take up particulate matter by 
phagocytosis [119]. Though they then degrade the pathogens, their main role in the immune 
system is not the clearance but maturation [120]. Mature dendritic cells activate T lymphocytes 
by displaying antigens on their surface and also provide other signals to alert of the specific 
antigen. This is the reason dendritic cells are also called antigen presenting cells. In certain 
conditions, macrophages can also act as antigen-presenting cells [121], but dendritic cells also 
function in initiating the adaptive immune response.  
2.2.2 Particulate design for stronger immune response on dendritic cell   
Immature dendritic cells endocytose through a variety of mechanisms and include 
nonspecific uptake by constitutive macropinocytosis [38], specific uptake via receptor-mediated 
endocytosis [122], and phagocytosis [123]. Soluble protein or peptide antigens in the solution 
internalized by dendritic cells via macropinocytosis show weak immunity due to poor antigen 
presentation; however, the particulate form is able to greatly improve the cross-presentation 
efficiency via phagocytosis leading to stronger immune response [124, 125]. In order to induce 
strong immune response through particulate form, several factors such as surface modification 
[126, 127], shape[128], surface curvature[129], surface charge [112, 113], size [130, 131], the 
addition of IL-1β [132] are important. Because of the potential for use these materials in vaccine 
development, we focus on immunogenic and targeting of dendritic cells. This is because 








2.3 Inflammatory signaling pathways 
2.3.1 Cytokine secretion 
Cytokines are molecules that are used for cell signaling or cell-to-cell communication, 
and can be grouped by structure or receptors. The cytokines secreted by dendritic cells in 
response to activation of pattern recognition receptors include Interlukin-1β (IL-1β), Interlukin-
12 (IL-12) and Tumor necrosis factor alpha (TNF-α) [133].  
IL-1β belongs to IL-1 family, the hematopoietins, the TNF family, and the type I 
interferons, and can be activated by innate immunity [134]. IL-12, known as a T cell-stimulating 
factor, is able to induce lymphocytes to produce IFN-γ and is able to amplify the activation of 
TH1 cells through Janus tyrosine kinase-signal transducer and activator of transcription (JAK-
STAT) intracellular signaling pathway [135]. TNF-α is a major pro-inflammatory cell signaling 
protein involved in early inflammatory events and is one of the cytokines that make up the acute 
phase reaction [136]. 
The IL-12 family of heterodimeric cytokines includes IL-12, IL-23, IL-27, and IL-35. 
The first three of these cytokines are produced primarily by dendritic cells, macrophages, and 
monocytes, while IL-35 is produced by regulatory T and regulatory B cells [137]. Each of the IL-
12 family cytokines consists of two subunits: an alpha chain (p19, p28, or p35) with a four alpha-
helix bundle structure and a beta chain (p40 or EBI3) that is homologous to the soluble class I 
cytokine receptor chains [138]. 
IL-12 is a secreted heterodimeric cytokine that contains disulfide-linked p35 and p40 
subunits, produced by macrophages, dendritic cells, monocytes, langerhans cells, neutrophils, 
keratinocytes, microglia, and non-germinal center B cells [138]. It acts through a receptor 





12 can enhance cytotoxic activity and induce Interferon-gamma (IFN-γ) production in natural 
killer cells, T-cells and dendritic epidermal T-cells [138]. In conjunction with IL-23 and IL-27, 
IL-12 promotes the development of a TH1 immune response; however, while TH1 cells continue 
to respond to signals during in infection, IL-12 is also needed to continuously sustain the 
effectiveness of differentiated TH1 cells [138]. 
2.3.2 Inflammasome activation 
The inflammasome is a multiprotein signaling complex belonging to the nucleotide-
binding and oligomerization domain (NOD)-like receptor family, and is expressed not only in 
immune cells but also in other types of cells, such as astrocytes, epithelial cells, fibroblasts, 
keratinocytes and neurons [139]. There are mainly four types of inflammasomes: NOD-like 
receptor family, pyrin domain containing 1 (NLRP1), NLRP3, NLR family CARD domain-
containing protein 4 (IPAF) and Interferon-inducible protein AIM2 (AIM2) [140]. Due to their 
components they can be separated into two groups: the NLR family including NLRP1, NLRP3 
and IPAF, as well as the pyrin and haematopoietic interferon-inducible nuclear antigens with 200 
amino-acid repeats (PYHIN family), like AIM2 [140].  
The NLRP3 inflammasome is activated by a wide range of stimuli including pathogen-
associated molecular patterns (PAMPs), such as viral RNA, damage-associated molecular 
patterns (DAMPs), such as ATP, fiber/particles, such as alum, metabolic products, such as 
monosodium urate crystals and environmental hazards, such as UV radiation. NLRP3 
inflammasome is the most widely characterized and implicated in inflammasome diseases [141, 
142]. Activation of NLRP3 inflammasome leads to the processing and secretion of IL-1β and IL-





shown to stimulate cytokine production by TH1, TH2 and TH17 cells and consequently contribute 
to immune activation [143]. 
The NLRP3 inflammasome has been described by three models: the channel model 
[144], the lysosomal rupture model [145] and the cellular stress model [146]. The channel model 
describes the direct activation of the NLRP3 inflammasome through entry of hydrophilic 
molecules into the cytosol [142]. This model, however, fails to explain activation of the NLRP3 
inflammasome through particulates that are too large to reach the cytosol through the newly 
formed pores. The lysosomal rupture model, proposed for particulates, suggests that 
phagocytosis of large crystals, particles or molecules leads to swelling and rupture of the 
lysosome and subsequent leakage of lysosomal enzymes into the cytosol [145]. The cellular 
stress model, which leads to the generation of reactive oxygen species aligned with changes in 
intracellular potassium concentration, has also been shown to contribute to inflammasome 
activation by particulates such as silica or alum [147]. 
Particulate vaccine delivery systems have been reported to act as adjuvants and to help 
promote immune responses through a variety of mechanisms such as enhanced uptake by 
dendritic cells, prolonged antigen presentation through a depot effect or targeting of specific cell 
compartments [104]. Recent studies showed that particulate systems with variant 
physicochemical properties could activate NLRP3 inflammasome through lysosomal damage, 
stimulate IL-1β secretion in vitro and further suggested that the NLRP3 inflammasome could be 
a common mechanism of action for particulate vaccine adjuvants [131]. However, not all 
particulate vaccine delivery systems can activate the NLRP3 inflammasome, and it was observed 
that CNP or alum, but not cubsomes or IFA, activate the NLRP3 inflammasome when given in 





NLRP3 inflammasome are surface charge [148], surface complexity [149], morphology [150], 






3. FABRICATION AND CHARACTERIZATION OF VIRAL PROTEIN 
ENCAPSULATED POLYMERIC MULTILAYER CAPSULE 
 
We hypothesize that viral protein-based particulate vaccine platform comprising of viral 
protein and biodegradable polymers provides safe and efficient method for inducing immune 
response in dendritic cells. In this chapter, recombinant SV40 VP1 viral protein was encapsulated 
into PLARG/DS through electrostatic interactions, and the physicochemical properties of the 
antigen-adjuvant complex were studied.  
3.1 Introduction 
Simian Virus 40 VP1 viral protein, a small, non-enveloped, double-strained DNA virus, 
belonging to the Polyomavirus family was chosen as the virus antigen. Previous work has shown 
that epitope modified SV40 VP1 virus-like particle presents as a natural adjuvant on cytotoxic T 
lymphocytes [55]. The capability of long-term gene expression in targeted cells and efficient 
incorporation of larger transgenes in vitro makes it a potential candidate for vaccine delivery 
with safety and flexibility than the capacity of the SV40 wild-type [48].  
Since subunit vaccines formed by a portion of the pathogens shows poor immunogenicity 
[153, 154], the antigen-adjuvant capsule was fabricated with the properties for biocompatibility 
and dendritic cell targeting. This subunit vaccine vehicle was constructed into a CaCO3-based 
PMLC using the LbL technique. SV40 VP1 was used as a model viral protein due to its low 
immune response, small and authentic viral structure, as well as its antigenic properties. 
Biodegradable poly-L-arginine/dextran sulfate polyelectrolyte pairs as adjuvants were used as 
they are capable of providing better biocompatibility and the ability to target dendritic cells. The 





polyelectrolytes were characterized using scanning electron microscopy, transmission electron 
microscopy, confocal laser scanning microscopy, zeta potential measurements and protein 
encapsulation efficiency. 
3.2 Materials and Methods 
3.2.1 Materials 
The E. coli strain containing recombinant Autographa californica multicapsid 
nucleopolyhedrovirus (AcMNPV) with the viral protein 1 gene of SV40 virus and a hexa 
histidine-tag (6xHis-tag) were purchased from Capital Bioscience Inc.  
Reagents for bacterial culture were purchased as below. Ampicillin, Sodium Salt was 
purchased from AMRESCO, Miller broth was purchased from Difco, Agar powder was 
purchased from Alfa Aesar and Glycerol and bicinchoninic acid (BCA) protein assay kits were 
purchased from Thermo Fisher Scientific. Dimethylformamide (DMF) was purchased from 
Sigma-Aldrich. E. coli DH10Bac™ E. coli strain, kanamycin, gentamicin, tetracycline, bluo-gal, 
Isopropyl β-D-1-thiogalactopyranoside  (IPTG), Qiagen endoFree plasmid maxi kits, cellfectin® 
II reagent and Alexa Fluor 680 labeled dextran, 10kDa were all purchased from Invitrogen. 
Regaents for insect cell culture were purchased as given below. Spodoptera frugiperda 
(Sf9) insect cells, Grace’s insect medium, and Western Blot secondary antibody, goat anti-rabbit 
antiserum conjugated to Alkaline Phosphatase were purchased from Invitrogen. Trypan blue, 
sodium phosphate monobasic and sodium phosphate dibasic hydrate were purchased from 
Sigma-Aldrich. Gibco Glutamax supplement, Penicillin-Streptomycin (10,000 U/mL), Nickel-






For LbL ecapsulation, calcium chloride, sodium carbonate, dextran sulfate sodium salt 
(DS, MW>500kDa and MW: 6.5-10kDa), poly-L-arginine (PLARG, MW>700kDa and MW: 5-
15kDa) and potassium chloride (KCl) were purchased from Sigma-Aldrich.  
Ethylenediaminetetraacetic acid (EDTA) and sodium chloride (NaCl) was purchased 
from BDH Chemicals. Instant blue stain for SDS Page was purchased from C.B.S. Scientific Co. 
Inc. Polyethylene glycol (PEG) virus precipitation kits and Western Blot primary antibody, 
rabbit anti-SV40 VP1 polyclonal antibody were purchased from Abcam. Imidazole and Tween 
20 were purchased from Acros Organics. Potassium dihydrogen phosphate was purchased from 
Alfa Aesar. 2% uranyl acetate and 10nm formvar and 1nm carbon with 400 square mesh grid 
(FCF400-Cu) were purchased from Electron Microscopy Sciences. 10K Microsep Advance 
Centrifugal Devices with Omega membrane was purchased from Pall Corporation. 
Ultrapure water used for all experiments was obtained from a Millipore system with a 
specific resistance 18.2MΩ/cm. 
3.2.2 Methods 
3.2.2.1 Spodoptera frugiperda (Sf9) cell culture 
Spodoptera frugiperda insect cell line is a clonal isolate derived from the parental 
Spodoptera frugiperda cell line IPLB-Sf-21-AE, and is a suitable host for expression of 
recombinant proteins from baculovirus expression vector systems. Spodoptera frugiperda insect 
cell line was grown as a monolayer culture at 27oC in Grace’s insect medium, supplemented, 
containing lactalbumin hydrolysate, yeastolate, L-glutamine and sodium bicarbonate with 5% 






3.2.2.2 Simian Virus 40 (SV40) VP1 Viral Protein Harvest by baculovirus expression vector 
system (BMES) System 
The recombinant Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) 
containing the VP1 gene of SV40 with an N-terminal addition of 6xHis-tag was used to produce 
SV40 VP1 viral protein, shown in Figure 4.  
 
 
Figure 4. Donor plasmid for generating recombinant SV40 VP1 viral protein. 
 
 
The competent E. coli, strain DH10Bac™ was used as a host for DNA plasmid to harvest 
baculovirus shuttle vector (bacmid). DH10Bac™ cells contains a bacmid with a mini-attTn7 
target site and a helper plasmid, pMON7124, which encodes the transposase and confers 
resistance to tetracycline. Once the DNA plasmid was transformed into DH10Bac™ cells, 
transposition occurs between the mini-Tn7 element on the DNA plasmid and the mini-attTn7 





transposition reaction occurs in the presence of transposition proteins supplied by the helper 
plasmid.  
The above process was carried out following the detailed protocol available in the 
Invitrogen, Max Efficiency DH10B Competent Cells manual, Invitrogen, Bac-to-Bac® 
Baculovirus Expression System manual, and EndoFree Plasmid Maxi kit manual. 
 
 




The concentration and growth of the E. coli was monitored by measuring absorbance at a 






on selective plates containing the 50μg/ml kanamycin, 7μg/ml gentamicin and 10μg/ml 
tetracycline, as well as the reagents, 100μg/ml blue-gal, and 40μg/ml IPTG. Additionally, the 
purification of either plasmid DNA or bacmid DNA was preceded by Qiagen endoFree plasmid 
maxi kits and the concentration was then determined by Nanodrop, exposed to ultraviolet light at 
a wavelength of 260 nm, shown as A260. The recombinant plasmid DNA and bacmid DNA stock 
were stored in -80oC freezer for long-term preservation. 
Once recombinant bacmid DNA was harvested, Sf9 transfection was carried out. 
Monolayer cell culture of Sf9 cell was first infected by recombinant bacmid DNA through 
cationic lipid, cellfectin® II reagent, with a density of 8x105 cells/well at 27oC. Once signs of 
infection, such as the detachment of cells from flasks or cell lysis, were observed, the medium 
containing viral protein was harvested. The supernatant was then collected as the P1 viral stock 
and separated from the cell debris by centrifugation at 500 x g for 5 min. The viral titer ranged 
from approximately 1 x 106 to 1 x 107 plaque-forming units/ml (pfu/ml). 
The infection was repeated with fresh Sf9 cells using the P1 viral stock with a cell density 
of 2x106 cells/well to obtain the P2 viral stock. The cultures which were infected by the P2 viral 
stock were harvested after signs of infection were observed, approximately 3 days post-infection. 
The cells were then collected by centrifugation at 500 x g for 5 min. Any unlysed viral protein 
was then released by carrying out three cycles of freeze-thawing and the cell debris was removed 
by centrifugation at 3,000 x g for 15 min. The supernatant was then purified on a nickel-
nitrilotriacetic acid (Ni-NTA) resin based on binding of the 6xHis-tag.  
Ni-NTA Agarose is a nickel-charged affinity resin that can be used to purify recombinant 
proteins containing a 6xHis sequence. Proteins bound to the resin may be eluted with either low 





both native and denaturing conditions. Ni-NTA uses the chelating ligand nitrilotriacetic acid 
coupled to a cross-linked 6% agarose resin that is suitable for use in batch and gravity flow 
applications. 
The harvested recombinant protein was stored at -80oC. The concentration of protein was 
measured by the BCA protein assay.  
In order to harvest higher concentration of viral protein, PEG virus precipitation kits and 
10K molecular weight cut-off (MWCO) spin tube were used as described in the user manuals.  
3.2.2.3 Simian Virus 40 (SV40) VP1 Viral Protein Identification Analysis 
SV40 VP1 viral protein production was confirmed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), Western Blot analysis and transmission 
electron microscopy (TEM) images. 
SDS-PAGE and Western Blot analysis were used to verify the identity of viral protein. 
Viral protein containing protein supernatants were resolved on 12% SDS-PAGE minigel using 
the Tris-Glycine buffer system, and visualized by instant blue stain. Gels were imaged on Gel 
DocTM EZ imager (Bio-Rad). Western Blot was utilized to confirm the identity of viral protein. 
The viral protein was first resolved by using SDS-PAGE as mentioned above, and then 
transferred to a nitrocellulose membrane by using the Quadra Mini-Vertical Slab Gel/Blotting 
System. Membranes were blocked in a solution of 5% dried milk powder in Tris-buffered saline 
containing 0.1% tween 20 and then probed with a 1:1000 dilution of the rabbit anti-SV40 VP1 
polyclonal antibody. A 1:5000 dilution of the secondary antibody (goat anti-rabbit IgG 
conjugated to Alkaline Phosphatase) was used and protein bands were visualized by developing 





The on-grid method of negative staining by 2% uranyl acetate was used to visualize small 
viral protein and determine its size with TEM. First, 400 mesh grids were treated with plasma to 
make them hydrophilic. Next, 2 μl of viral protein was placed on copper-coated grids, allowed to 
adsorb to the grid for 30 seconds and the excess removed by blotting with a filter paper. The 
samples were then negatively stained with a 2% uranyl acetate, incubated for 45 seconds, the 
extra medium removed, and then air-dried for 1 min. Lastly, the samples were examined with a 
JEOL 1200 EX TEM operating at 100 kV.  
3.2.2.4 Fabrication of Calcium carbonate (CaCO3) Microparticles 
Polymeric multilayer capsules were built on CaCO3 microtemplates as a sacrificial core. 
CaCO3 microparticles were synthesized according to Volodkin et al. [103] by rapidly adding 
0.33M Na2CO3 solution into an equal volume of 0.33M solution of CaCl2 at room temperature. 
After intense agitation on a magnetic stirrer with 650 rpm for 30 seconds, the precipitate was 
filtered for 30 min. The solution containing CaCO3 microparticles was centrifuged and the pellet 
thoroughly washed with DI water. The average size of CaCO3 microparticles was ~ 4 µm in 
diameter. In order to fabricate smaller CaCO3 microparticles, the agitation time was increased 
from 30 s to 60 s, while keeping the other steps unchanged. This resulted in CaCO3 
microparticles with average size ranging from 1 to 4 µm in diameter and ~ 95% yield. 
3.2.2.5 Polymeric Multilayer Capsule (PMLC) Encapsulation 
The layer formation was constructed by LbL technique. Dextran sulfate and Poly-L-
Arginine were prepared as the polyanion and polycation, respectively. The concentration of DS 
and PLARG was 2 mg/ml and 1 mg/ml, respectively, dissolved in 0.5 M NaCl (pH 6.0). The 





CaCO3 microspheres were freshly made as described above, and resuspended in 10 ml 
NaCl solution. Macromolecule capsules were built up by adding 0.25 mg/ml viral protein 
together with 1 ml PLARG (positively charged PE solution) onto the CaCO3 microtemplates at a 
protein/CaCO3 weight ratio of 4%. Suspensions were thoroughly agitated on a shaker for 20 
minutes at room temperature and followed by centrifugation and sonication with 0.5M NaCl. To 
avoid particle aggregation, the centrifuged pellets were vortexed every time before the addition 
of next layer and after decanting the supernatant. The same process was alternatively applied to 1 
ml DS and 1 ml PLARG solution alone, until 5 layers were deposited (2.5 bi-layers). The core 
removal step was carried out using 0.05 M EDTA. After 30 min agitation, the capsules were 
centrifuged, the supernatant was removed, and resuspended in fresh EDTA. The EDTA core 
removal step was repeated an additional two times. The resultant suspensions of PMLCs were 
washed twice with DI water and finally stored at 4oC in 0.5M NaCl. The concentration of viral 
protein was then measured by the BCA protein assay kit and quantified using the infinite M200 
Pro microplate reader (Tecan).  
 
 
Figure 6. Scheme of PMLCs fabrication. Step A: CaCO3 crystallization, Step B: Protein 
precipitation, Step C: Encapsulation by Layer-by-Layer technology, Step D: Core dissolution. 
 





We evaluated the effect of varying the MW of the polymers on PMLC formation. 
Different capsules were formed using different combination of the polyelectrolytes, as shown in 
Table 1. 
Additionally, in order to study the influence of the distribution of viral protein, 2VP-
PMLC was fabricated. The fabrication scheme used for 2VP-PMLC was similar to VP-PMLC, 
only that the viral protein concentration was different and an addition viral protein layer was 
used. Viral protein was co-precipitated with PLARG both in the first and third layers but only 
with half amount of viral protein to keep the same total concentration of the viral protein. 
To study the in vitro release profile of the VP-PMLCs, 20 nm fluorescent silica bead was 
used to mimic the size distribution of the viral protein. Alexa Fluor 488 labeled dextran (10 kDa) 
and Fluorescein labeled dextran (500kDa) were applied as the second layer. 
3.2.2.6 Polymeric Multilayer Capsule (PMLC) Identification Analysis  
Surface and elemental analysis was analyzed by field emission scanning electron 
microscope (FE-SEM) and Energy-dispersive X-ray spectroscopy (EDS). One drop of sample 
was first applied on the silicon wafer, and air dried overnight. Then samples were conducted 
with a JEOL JSM-7500F, an ultra-high resolution FE-SEM equipped with a high brightness 
conical field emission gun and a low aberration conical objective lens. The sample preparation 
for EDS was the same as FE-SEM, and the analysis was done with an Oxford EDS system 
equipped with X-ray mapping and digital imaging. 
Zeta-potential measurements was used with the microparticles during LbL encapsulation. 
50 µl of samples were suspended in 1 mM fresh prepared KCl and the electrophoretic mobility 





Confocal Laser Scanning Microscope (CLSM) was used to investigate the distribution of 
polyelectrolyte via LbL fabrication. In order to understand the microparticle structure, Alexa 
Fluor 680 labeled dextran, with MW of 10 kDa and ~4.6 nm in diameter [156] was applied to 2nd 
layer of PMLCs. One drop of well-suspended Alexa Fluor 680-labeled-VP-PMLC was spread 
and placed on a glass slide. Confocal micrographs were taken with an Olympus FV1000 
Confocal Microscope, equipped with a 100x oil immersion objective with a numerical aperture 
of 1.4. Data were analyzed by FV10-ASW software. Alexa Fluor® 680 was detected at an 
excitation wavelength of 633 nm. 
3.3 Results 
3.3.1 SV40 VP1 harvest 
SV40 VP1 viral protein was harvested through a baculovirus expression vector system 
(BEVS) Sf9 insect cell line. Before transfection by the BEVS system, the bacmid was first 
harvested by growing DH10Bac™ E. coli overnight, followed by purification using EndoFree® 
Plasmid kits. The OD600 value was 1.3 and the final mass of the purified recombinant bacmid 
was approximately 30 µg. 
The Sf9 insect cell line is a clonal isolate derived from the parental Spodoptera 
frugiperda cell line IPLB-Sf-21-AE. It is a suitable host for expression of recombinant proteins 
from the baculovirus expression vector system. The bacmid was transfected using the cellfectin 
II cationic lipid reagent. Compared to mammalian expression system, the baculovirus expression 
vector system provided an easier way to amplify the viral stock to obtain higher viral titers, as 






At three days post-infection of 2 x 107 Sf9 cells cells, approximately 0.5 mg of the 
purified recombinant SV40 VP1 viral protein was harvested by using 0.4 ml P2 viral stock with a 
titer ranging from 1 x 107 to 1 x 108 pfu/ml. In order to increase the viral protein concentration, 
PEG virus precipitation kits were used to increase P2 viral titer on bacmid, and 10K molecular 
weight cut-off (MWCO) spin tube was used to concentrate the SV40 VP1 viral protein to reach a 
concentration up to 0.4 mg/ml. 
The size of the SV40 VP1 viral protein was then verified by TEM with negative stain. 
Negative staining is achieved when heavy staining ions are repelled by the charged groups of the 
specimen and tracking the trace of the biological molecules. Some well-known negative stains 
include ammonium molybdate, uranyl acetate, uranyl formate, phosphotungstic acid, osmium 
tetroxide, osmium ferricyanide [157] and auroglucothionate. Figure 7 illustrates the morphology 
of SV40 VP1 viral protein and shows the size is uniformly around 20 nm in diameter.  
 
 








Viruses have the ability to enter the human cells. The capsid protein, e.g. viral protein 1, 
is especially important as it is responsible for attachment to host cells. Moreover, the capsid 
protein is capable of self-assembling into a virus-like particle which is authentic as the wild-type 
viral capsid protein even without the existence of the infectious genome. This makes virus-like 
particles a potential candidate for vaccines. However, using different solvent conditions, such as 
pH, calcium addition and ionic strength, the capsid proteins could be assembled into different 
unit numbers [158]. In this study, taking advantages of smaller particles, SV40 VP1 capsomeres 
were applied as a model viral protein. 
The identification of SV40 VP1 viral protein was then examined by SDS-PAGE and 
Western Blot, shown in Figure 8. From Figure (8a), with the comparison to standard MW protein 
label, the SDS-PAGE gel shows that the molecular weight of the SV40 VP1 viral protein is 
around 49 kDa. Moreover, based on lane W from the SDS-PAGE gel shown in Figure (8a), there 
is no protein loss is observed in the washing steps; however, compared lane L to lane VP, the 
color and the thickness of the lane reveals that more viral protein remained on the gel. Therefore, 
though Ni-NTA resin provided a convenient way to purify 6xhis-tag proteins, the harvesting 
efficiency was not high. From Figure (8b), the VP1 viral protein was verified by Western 
Blotting. These results demonstrate that SV40 VP1 capsomere was successfully formed using the 







Figure 8. Expression of the SV40 VP1 viral protein in insect cells. Viral protein was harvested 3 
days post-infection with the recombinant AcMNPV expressing SV40 VP1. An extract of ~107 Sf9 
infected cells were analyzed through Ni-NTA resin-purified. (a) SDS-PAGE gel of resin-purified 
SV40 VP1 was stained with instant blue stain. Lanes of a 12% SDS-PAGE gel were loaded as 
followed. M: molecular weight markers; L: cell lysates before purification; B: supernatant after 
cell lysates bond to the Ni-NTA resin; W: supernatant of Ni-NTA wash buffer with bond cell 
lysates resin; VP: cell lysates after purification. (b) Western blot of resin-purified SV40 VP1 was 
detected with rabbit anti-SV40 VP1 polyclonal from a 12% SDS-PAGE. 
 
 
3.3.2 Fabrication of viral protein-based polymeric multilayer capsule 
Polymeric multilayer capsules (PMLCs) were first developed in 2004 [98]. This approach 
of encapsulation provides a safer, versatile as well as stable method for enzymatic assays [100], 
drug delivery [105, 107, 159-168], and vaccine delivery [38, 41]. This formulation helps avoid 
harsh conditions for core removal, like extreme pH [167, 169], or oxidizing agents [170]. 
Antigen-loaded PMLCs were synthesized as shown in Figure 9. Dextran and Poly-L-Arginine 
were used as the polyanion and polycation, respectively for LbL encapsulation.  
3.3.2.1 Porous structure of viral protein-based polymeric multilayer capsule (VP-PMLC) 
Highly homogeneous and porous inorganic CaCO3 microparticles were crystallized from 








kDa M     L     B      W    VP 
 







stirring soluble salts containing Ca2+ and CO3
2-, an amorphous nanoprecipitate was formed 
instantly leading to a microparticle nucleus. The crystal growth was then transformed slowly by 
recrystallizing into rhombohedral calcite crystals in DI water. To get CaCO3 microspheres, the 
recrystallization was then terminated by filtering and washing with DI water. The morphology of 
CaCO3 microparticles (Figure 9) was an even uniform spherical microparticles that were ~4 μm 
in diameter.  
 
 
Figure 9. Scanning electron microscopy images of CaCO3 microparticles with an average size of 
4 µm: (a) in overview, scale bar, 10 µm (B) single particle, scale bar, 1 µm. 
 
 
The properties of the microparticles were altered by changing the conditions of 
formation. The speed and time of stirring were two factors that altered the size of nuclei. The 
longer the time or the higher the speed of agitation, the smaller size of the nuclei formed due to 
more intermixing of salts, which further resulted in smaller sized crystals. Therefore, under the 
same salt concentration and the speed of agitation, when the agitation time increased from 30 s to 
60 s, the size of CaCO3 changed from 4 µm monodisperse porous spherical microparticles to 1 to 
4 µm polydisperse porous spherical microparticles. The results are in agreement with Volodkin 






spherical microparticles could be achieved only with the sizes ranging from 3 to 20 µm in 
diameter. The SEM images were shown in Figure 10.  
 
 
Figure 10. Scanning electron microscopy images of CaCO3 microparticles fabricated by different 
preparation conditions. (a) By 30 seconds of irritation, the mean size of CaCO3 microparticles 
was 4 µm mono-disperse porous spherical; (b) By 60 seconds of irritation, the mean size of 
CaCO3 microparticles was 1 to 4 µm poly-disperse porous spherical. Scale bar, 5 µm. 
 
 
Viral protein precipitated together with positively charged polyelectrolyte were then 
applied onto CaCO3 templates. The surface charge of the CaCO3 microparticles and SV40 VP1 
viral protein was approximately -22.4 mV and -4.5 mV, respectively, measured by ξ-potential 
measurements in KCl solution. The data of the slightly negatively charged SV40 VP1 viral 
protein was consistent with predictions that with a pI of 6.8 [58], the VP1 protein presented 
negative to neutral surface charges in a pH 6 solution. Despite being negatively charged, the 
boundaries, which indicate the position of the CaCO3 surface, showed preferential sites for viral 
protein to initiate accumulation, resulting in surface-mediated nucleation followed by 







PLARG, a positively charged polyelectrolyte, was chosen as the first layer and co-
precipitated with negatively charged viral protein for better encapsulation rate. After protein 
precipitated onto the CaCO3 microtemplates, oppositely charged PEs were applied sequentially. 
When considering the outermost layer for vaccine vehicle design, booster injection and cell 
targeting performance played crucial factors. Due to the negatively charged cell surface, a 
positively charged polyelectrolyte shows potential to induce more non-specific interactions 
[171]. Moreover, it has been shown that poly-L-arginine can be used for repeated vaccination and 
resulted in no antibody or T cell responses [109]. Therefore, in this study, the VP-PMLCs were 
designed as the 2.5 bi-layer PLARG/DS capsules by sequential application of oppositely charged 
polyelectrolytes, with the last layer being a PLARG layer. Alternating charges of zeta-potential 
measurements during the adsorption of each layer were determined, providing the evidence of 
the successful adsorption of polyelectrolytes on each layer, shown in Figure 11. 
 
 
Figure 11. ξ-potential versus layer number for the layer-by-layer self-assembly of Dextran and 






The SEM image in Figure 12 shows the morphology after encapsulation of five 
polyelectrolyte layers onto 4 μm CaCO3 core. Compared to the untreated CaCO3 microspheres, 
shown in Figure 9(b), a rougher surface was observed as surface coating but the porous surface 
still could be seen. 
 
 
Figure 12. Scanning electron microscopy images of VP-PMLCs treated by 5 layers of 
polyelectrolytes, scale bar, 1 µm. 
 
 
Alexa Fluor 680 labeled Dextran with MW of 10 kDa was further applied to the 2nd layer 
for distribution studies, while keeping the other layers of polyelectrolytes the same. After 
achieving 2.5 bi-layer VP-PMLCs, confocal laser scanning microscope images were taken and 
the intensity of fluorescence was analyzed to observe the localization of fluorescent Dextran 







Figure 13. (a) Confocal laser scanning microscope images of  VP-PMLCs encapsulated with 




The confocal laser scanning microscope images suggested that fluorescent Dextran 
deposited as the 2nd layer still could penetrate through PLARG layer and deposit at the center of 
the CaCO3 microparticles uniformly. Additionally, Volodkin et al. found that the pore size 
distribution of 4µm CaCO3 particles was between  20-60 nm [172]. The size of SV40 VP1 
capsomere is around 20 nm in diameter. Moreover, taking advantages to the high surface area of 
CaCO3 microplates, it is reasonable to believe the SV40 VP1 can be deposited within the CaCO3 
microparticles uniformly.  
Core dissolution was applied by treating with EDTA (Figure 14). Compared to other 
sacrificial models that use harsh conditions like extreme pH value, organic solvents or oxidizing 
agents for core removal, washing with EDTA provide a mild condition that results in lesser loss 
in particles. EDTA has the ability to sequester metal ions, such as Ca2+ and Fe3+ etc. After 










Figure 14. Chemical structure of ethylenediaminetetraacetic acid (EDTA) 
 
 
The surface charge of the final capsule was 10 ± 6 mV, resulting in non-aggregated 
capsules. Core decomposition was demonstrated by TEM, SEM, and EDS, as shown in Figure 
15. Figure (15a) and (15b) show TEM images before and after core removal. Before core 
removal, the particles show a solid, dark color; however, after core removal, the particles become 
semi-transparent. Figure (15c) and (15d) also show that the particle size shrank after core 
decomposition. However, neither TEM nor SEM images could accurately demonstrate complete 
core removal level. Therefore, we used EDS for core removal detection. The Ca2+ peaks in the 
EDS spectra show the existence of the CaCO3 core, shown in Figure (15e) and (15f). The high 
peaks seen in EDS, shown in Figure (15e), demonstrated the existence of the CaCO3 
microparticles before core dissolution and that no Ca2+ was detected after core decomposition 







Figure 15. Transmission electron microscopy images, scanning electron microscopy images and 
energy-dispersive spectroscopy of VP-PMLCs (a, c, e) before and (b, d, f) after core decomposed. 
Scale bar, 3 µm. 
 
 
Together the ξ-potential, TEM, SEM, EDS and CLSM analysis show that the VP-PMLCs 
could be successfully fabricated using the LbL technique. Moreover, after encapsulation with 
polyelectrolytes, these VP-PMLCs have been reported to be stable and show no further 













3.3.2.2 Encapsulation efficiency of viral protein-based polymeric multilayer capsule (VP-PMLC) 
by different molecule weight of polymers 
Protein encapsulation efficiency is defined as the amount of protein encapsulated by 
PMLCs. It is a crucial factor in determining the successful assembly of VP-PMLC. The protein 
encapsulation efficiency was calculated as follows: 
 
E = [(Amount of encapsulated protein)/(Total amount of fed protein)] x 100%  
Parameters affecting protein encapsulation efficiency include the selection of 
polyelectrolyte pairs and their molecular weight, number of layers, the approaches of protein 
adsorption, the size of protein, and pH of the system. In this work, the protein encapsulation 
efficiency was addressed by varying MW of polyelectrolytes and using different methods for 
viral protein adsorption.  
To study on the mechanism of protein encapsulation and release, two approaches of 
fabrication were used: (i) viral protein encapsulated together with PLARG in the 1
st layer onto 
CaCO3 microparticles (CaCO3/VP/PLARG), followed by layer-by-layer assembly until 2.5 bi-
layer PLARG/DS shell was formed, denoted as “VP-PMLC”, and (ii) “2VP-PMLC” where viral 
protein adsorbed together with PLARG in both of the 1
st and 3rd layers, followed again by layer-
by-layer assembly until 2.5 bi-layer PLARG/DS was formed. The encapsulation efficiency from 
both approaches was then compared between PLARG/DS polyelectrolyte pairs with different 








Table 1. Design of polymeric multilayer capsules   
Denotation Composition 
(PMLC)H [CaCO3 - (PLARG)H] - (DS)H - (PLARG)H - (DS)H - (PLARG)H 
(PMLC)C [CaCO3 - (PLARG)H] - (DS)H - (PLARG)L - (DS)L - (PLARG)L 
(PMLC)L [CaCO3 - (PLARG)L] - (DS)L - (PLARG)L - (DS)L - (PLARG)L  
(VP-PMLC)H [CaCO3 - VP - (PLARG)H] - (DS)H - (PLARG)H - (DS)H - (PLARG)H 
(VP-PMLC)C [CaCO3 - VP - (PLARG)H] - (DS)H - (PLARG)L - (DS)L - (PLARG)L 
(VP-PMLC)L [CaCO3 - VP - (PLARG)L] - (DS)L - (PLARG)L - (DS)L - (PLARG)L  
(2VP-PMLC)H [CaCO3 - VP - (PLARG)H] - (DS)H - [VP - (PLARG)H] - (DS)H - (PLARG)H 
(2VP-PMLC)L [CaCO3 - VP - (PLARG)L] - (DS)L - [VP - (PLARG)L] - (DS)L - (PLARG)L  
 
After encapsulation, the viral protein is located inside the particles. However, due to the 
porous structure, the protein concentration of VP-PMLCs can still be determined by the micro 
BCA protein assay. The concentration of viral protein inside particles under the different 
conditions (different MW of polyelectrolytes or different methods for encapsulation) is shown in 
Table 2.  
 
Table 2. Concentration and encapsulation efficiency of SV40 VP1 Viral Protein in 2.5 Bi-Layer 
of Polymeric Multilayer Capsulesa 
Capsule Loading Approach (VP-PMLC)L (VP-PMLC)H (2VP-PMLC)L (2VP-PMLC)H 
Protein Concentration (mg/ml) 0.145 0.158 0.088 0.133 
Encapsulation Efficiency (%) 58% 63% 35% 53% 
a. Total initial amount of SV40 VP1 viral protein was 0.25 mg in each sample. Each data 






Table 2 shows that polyelectrolyte pairs comprised of high MW provides higher retaining 
ability in comparison with those composed of low molecular ones. The highest encapsulation 
efficiency of PMLCs is around 63% and is observed with (VP-PMLC)H. This can be attributed to 
the increasing entanglement and viscosity of high molecular weight polyelectrolytes. Although a 
smaller pore size can be attained with a shorter deposition time; however, the relationship 
between pore size and MW of polyelectrolytes depends on the polymer itself. For example, 
higher MW of polycyclic aromatic hydrocarbons show larger pore size, but opposite results were 
observed with poly(acrylic acid) [173].  
Adding viral protein in different layers could also influence the viral protein 
encapsulation efficiency. Table 2 shows that 2VP-PMLC has a lower viral protein concentration 
inside the particle than VP-PMLC. However, since different antigen encapsulation efficiency 
was obtained with the different capsules, the antigen amount after normalization to the particle 
number is comparable (~0.008 - 0.01 mg/20x105 particles). This means that even with the same 
amount of CaCO3 core and viral protein at the beginning, different final particle amounts were 
obtained, and further confirmed that the ability of the encapsulation efficiency on each single 
capsule is similar.    
In order to further investigate on protein loss, the protein concentration of supernatants 







Figure 16. Protein loss measurement applied on supernatants from each wash step. Initial protein 
amount was 0.25 mg in total.  
 
 
Recent studies presented that CaCO3 synthesized together with protein 
(CaCl2/Na2CO3/protein) led to more protein loss after core dissolution [38, 174]. However, by 
co-precipitating protein and PLARG directly onto CaCO3 crystals (CaCO3/VP/PLARG), protein 
loss was minimized in the core dissolving process, shown in Figure 16. This might be attributed 
to fewer interactions between the viral protein and calcium ions. By using this approach, it could 
be predicted that more viral protein would either penetrate into the center of porous CaCO3, or 
adhere onto the surface of CaCO3 microparticle and polyelectrolytes. Therefore, it was 
reasonable to observe more protein loss in either the 1st layer of PLARG for VP-PMLCs or both 
1st and 3rd layers of PLARG for 2VP-PMLCs. Therefore, 2VP-PMLC provided two viral protein 





precipitation step, protein was released immediately after the deposition steps, but little loss was 
found in the following washing steps.  
In comparison with dextran and Poly-L-Arginine polyelectrolytes, it was shown that more 
protein was lost in PLARG layers. For example, for the VP-PMLC series, PLARG fabricated as 
the 3rd and 5th layers resulted in almost twice protein loss than Dextran in the 2nd and 4th layers, 
except for the 5th layer on high MW of PMLCs. As for high MW of capsules, the 5th layer of 
protein loss is barely seen, showing that high MW of PMLCs are able to secure viral protein 
inside the particles then low MW of PMLCs on the 5th layer. 
Therefore, we conclude that layers with low MW of PLARG/DS polyelectrolyte pairs, 
viral protein or PLARG showed a higher protein loss. Since VP-PMLC presented higher 
encapsulation efficiency than 2VP-PMLC, a certain amount of protein appears to be lost at each 
protein co-precipitation step. To attain higher encapsulation efficiency, high molecular weight 
polyelectrolyte pairs with a one-time protein loading should be used. 
3.4 Summary 
SV40 VP1 viral protein of ~20 nm diameter were successfully harvested by baculovirus 
expression vector system in insect cells. Viral protein-based polymeric multilayer capsules 
serving as vaccine vehicle was successfully developed for the first time. PLARG/DS 
polyelectrolyte pairs, as well as SV40 VP1 viral protein were assembled onto CaCO3 sacrificial 
porous microparticles through LbL fabrication, followed by EDTA core removal. The VP-PMLC 
was a porous sphere, with diameters ranging from 1-4 μm in diameter and a positively charged 
surface. To optimize protein encapsulation efficiency, two capsule formulations and varying 
molecular weight of PLARG/DS polyelectrolyte pairs were investigated. In this study, the viral 





high molecular weight polyelectrolyte pairs with protein deposited together in the first layer (VP-
PMLC)H. But when normalized to the total number of particles, the encapsulation efficiency in 





4. IN VITRO IMMUNITY EVALUATION OF PMLC PARTICLES 
 
The results in Chapter 3 showed successful fabrication and characterization of SV40 VP1 
viral protein-based PMLCs. This Chapter discusses in vitro studies with immune cells to evaluate 
their effectiveness for vaccine delivery.  
4.1 Introduction 
The primary goal of a vaccine is to prepare the body to clear an infectious agent without 
allowing disease symptoms to be expressed. When a person is immunized, APCs recognize any 
pathogens and produces specific antibodies to clear the antigens and protect the body against 
further infection [175, 176]. However, if there are no antibodies for the antigen, it will take 
several days for the body to recognize the antigen, generate antibodies, and to mount an antibody 
response to clear the pathogen from the body. While this may not be very significant for some 
viral pathogens, for other pathogens like the measles virus [177] or whooping cough bacteria 
[178], a delay in initiating antibody-mediated immune response can have significant 
consequence and even lead to mortality. This underscores the importance of vaccines. 
In order to generate antibodies, cells of the adaptive immune system need to be 
stimulated by components of the innate immunity system [116, 179]. Therefore, the first defense 
line of immunity is stimulation of antigen presenting cells like dendritic cells are the bridge 
between innate and adaptive immunity and would be the cells that respond first to a vaccine. 
In this Chapter, results from in vitro studies on co-incubation PMLCs with either bone 
marrow derived dendritic cells or murine DC2.4 dendritic cell line are shown. The effect of 





cell viability measurements, and expression of the CD40 and CD86 surface marker proteins in 
dendritic cells upon stimulation.  
4.2 Materials and methods 
4.2.1 Materials 
The DC2.4 dendritic cell line was provided by Dr. Robert Alaniz at the Texas A&M 
Health Science Center. Primary bone marrow derived dendritic cell were isolated and cultured 
from marrow of C57BL/6 mice that were kindly donated by Dr. Alaniz’s lab from their ongoing 
experiments.  
Gibco Glutamax supplement, Penicillin-Streptomycin (10,000 U/mL), BCA protein assay 
kits and Lactate dehydrogenase (LDH) cytotoxicity assay kits were purchased from Thermo 
Fisher Scientific. 
Antibodies for flow cytometry analysis are listed below: rat anti-mouse CD16/CD32 
(mouse BD Fc block), Alexa Fluor 700 hamster anti-mouse CD11c, APC rat anti-mouse CD40 
and PE-Cy7 rat anti-mouse CD86 were purchased from BD Biosciences. Recombinant mouse 
granulocyte-macrophage colony-stimulating factor (GM-CSF) was purchased from BD 
Biosciences as well. 
Alexa Fluor 488 labeled dextran (10kDa) and Fluorescein labeled dextran (500kDa) were 
purchased from Invitrogen. LPS from E. coli O55:B5 and 2-well chamber slides were purchased 
from Sigma-Aldrich. Cy5-labeled 20 nm silica beads were purchased from NANOCS INC. 
RPMI 1640 without L-glutamine was purchased from Lonza.  
Ultrapure water used for all experiments was obtained from a Millipore system with a 







4.2.2.1 Mice Bone Marrow Cell Isolation  
Bone marrow cells were flushed out of the femurs and tibias into complete medium and 
pipetted vigorously to make a single cell suspension, and then passed through a 70 μm cell 
strainer. Cells were centrifuged at 1300 rpm for 10 min and resuspended in ACK lysis buffer. 
After 4 min incubation at room temperature, cells were washed twice with complete growth 
medium, resuspended in growth medium, and ready for culture.  
4.2.2.2 Mice bone marrow derived dendritic cells harvest 
A single-cell suspension of mice freshly isolated bone marrow stem cell was seeded at a 
density of ~2x106 cells/petri dish in 10 ml culture of RPMI 1640 medium containing 10% FBS, 
2mM glutaMax, 100 U/ml penicillin/streptomycin and 20ng/ml GM-CSF. Cells were 
differentiated into BMDCs at 37oC in 5% CO2 environment for 6 days. 
At day 2, half of the culture medium was replenished, while taking care to exclude 
monocytes. At day 4, an additional 10 ml of fresh culture medium was added. At day 6, cells 
were centrifuged at 300 x g for 8 min. The cell pellet contained immature BMDCs that was used 
in subsequent experiments. 
4.2.2.3 DC2.4 dendritic cell line harvest 
DC2.4 dendritic cells were maintained at 37oC in 5% CO2 environment with the same 
growth medium as BMDCs but with 5% FBS. Medium was replenished every three days till cells 
reached ~80% confluence. For routine passaging, cells were trypsinized, centrifuged at 300 x g 







4.2.2.4 Lactate dehydrogenase (LDH) cytotoxicity assay kit 
The lactate dehydrogenase (LDH) cytotoxicity assay kit was used to estimate cell 
viability, based on the levels of LDH in the cell culture supernatant. Since LDH is an 
intracellular enzyme, any LDH in the supernatant must have been released from a dead cell; 
therefore, cultures will lower viability would have higher levels of LDH in the supernatant. The 
optimized protocol given by the manufacturer was used for the assay.  
All experiments were run in triplicate. BMDCs were seeded in the 96-well flat bottom 
culture plates at a density of ~104 cells/well. Two ratios of PMLCs or VP-PMLCs to cells were 
tested (20:1 and 100:1) and the viral protein concentration was 0.1 mg/ml. BMDCs co-treated 
with viral protein and particles were incubated at 37oC in 5% CO2 environment for 24h. 
4.2.2.5 Release profile by confocal laser scanning microscope 
Confocal Laser Scanning Microscope (CLSM) was used to investigate the distribution of 
microparticles after cell phagocytosis. In order to visualize microparticles in vitro, fluorescent 
materials - Alexa Fluor 488 labeled dextran (10kDa), Fluorescein labeled dextran (500kDa), and 
20nm Cy5-labeled silica beads - were used to fabricate microparticles. For five layers of 
encapsulation, fluorescent dextran was used in the 2nd layer to investigate particle structure and 
the breakdown of particles. The 20 nm fluorescent silica beads were used to mimic the viral 
protein for release. Before carrying out in vitro release experiments, ξ-potential and SEM were 
applied to verify the structure of the fluorescent particles as described in 3.2.2.6 (Polymeric 
Multilayer Capsule Identification Analysis section).  
After verification, fluorescent particles were then co-cultured with DC2.4 dendritic cells 
in multiple two-well chamber slides in parallel. The DC2.4 dendritic cell density was ~2x104 





to 72h. At 4, 24, 48, and 72h, the culture medium was aspirated from one set of cultures, the cells 
washed twice with PBS, and fixed with 4% PFA in the dark for 15 min.  
The slide chamber was placed on the stage of a Olympus FV1000 Confocal Microscope 
with a numerical aperture of 1.4. The excitation wavelength was 488 nm for detecting Alexa 
Fluor 488 labeled 10 kDa dextran, 515 nm for Fluorescein labeled 500kDa dextran, and 633 nm 
for detecting 20nm Cy5-labeled silica beads. 
4.2.2.6 Flow cytometry analysis by antigen targeting to mice bone marrow derived dendritic 
cells (BMDCs) 
Antigen targeting to BMDCs was evaluated by flow cytometry using the following 
antibodies: Alexa Fluor 700 hamster anti-mouse CD11c, APC rat anti-mouse CD40 and PE-Cy7 
rat anti-mouse CD86. BMDCs were seeded in 96-well round bottom culture plates with a density 
of ~105/well. LPS (1000 ng/ml) was used the positive control, and the ratio of PMLCs, VP-
PMLCs to cells was 20:1 and the viral protein concentration was 0.1 mg/ml. Co-treated BMDCs 
were then cultured at 37oC in 5% CO2 for another 24h. 
After 24h, the treated BMDCs were centrifuged at 300 x g for 3 min, followed by two 
PBS wash steps. Before incubating with antibodies, 100 μl of 100X Fc block dilution in 10% 
PBSA was added to each well to minimize non-specific binding. The plate was then incubated on 
the ice for 10 min, followed by a PBSA wash. Antibodies were prepared at 1:100 dilution in 
PBSA, and added 50μl into each well. Cells were incubated in the dark on ice for 30 min, 
washed twice with PBSA, and fixed with 200 μl of 1% PFA. The cells were fixed for 20 min in 
the dark on ice, centrifuged, and re-suspended in PBSA for flow cytometry. Data acquisition was 
performed by using BD Fortessa X-20 in the TAMSHC College of Medicine Cell Analysis 






4.3.1 Cell viability through BMDC 
Since an antigen alone might be toxic to cells, PLMCs were used to form matrix 
microcapsules. A polycation was used as the outermost layer to provide more non-specific cell 
targeting ability. However, Fisher et al. reported that polycation with high MW, high charge 
density, and flexibility, could cause higher cytotoxicity [180]. Therefore, the VP-PMLCs with 
different molecular weights of PLARG/DS polyelectrolyte pairs were used to study cell viability 
using BMDCs. The cell viability of bone marrow derived dendritic cells after exposure to 3μm in 
diameter microparticles for 24h was evaluated. In vitro cell compatibility studies and LDH 
release is shown in Figure 17. 
 
 
Figure 17. Viability of BMDCs incubated with PMLCs with particle/cell ratio 20:1. Cytotoxicity 
was evaluated by co-culturing mice BMDCs with either VP (black color), PMLCs (white color), 
VP-PMLCs (light grey color) and 2VP-PMLCs (dark grey color), respectively, for 24h. The viral 
protein concentration was 0.1 μg/ml and the ratio of particle to cell was 20. Two molecular 






BMDC cells co-cultured with 0.1 mg/mL of VP showed relatively high viability. This 
could be due to the nature of SV40 VP1 viral protein, as although it can transform mouse cells in 
vitro, it is not able to induce tumor growth [181]. Therefore, at this concentration, SV40 VP1 
viral protein was not toxic to BMDCs.  Compared to different MW of PMLCs, (PMLC)H, 
(PMLC)C and (PMLC)L with a microparticle to cell ratio of 20:1 (shown in Figure 17 as white 
columns), low MW of capsules showed higher viability than high MW ones. Similar 
observations were made with VP-PMLC (Figure 17, light grey color columns). This finding also 
supports the results from Fisher et al, who mentioned that high MW of polymers tend to be more 
toxic [180].  
Next, PMLC, VP-PMLC, and 2VP-PMLC were compared to study the viability influence 
caused by different locations of viral protein. The first group (high MW PMLC) shown in Figure 
17 shows that the presence of the viral protein caused lower cytotoxicity; this was also observed 
in composite MW, as well as low MW PMLC. Taking the capsule number into consideration, the 
viral protein concentration in each capsule ranged from 0.008 to 0.01 mg/ml while the 
concentration of viral protein alone is 0.1 mg/ml. 
The same experiment was repeated with the ratio of particle/cell increased to 100 and 
keeping the viral protein concentration at 0.1 mg/ml. Figure 18 shows the cytotoxicity in 
BMDCs for 24h. Comparing to Figure 17, Figure 18 shows an overall reduction in viability, with 
the averaged viability decreases to 70%. The trend observed in Figure 17 still can be found in 
Figure 18; however, due to the large amount of particles, the influence of MW of the polymers 







Figure 18. Viability of BMDCs incubated with VP (black color), PMLCs (white color), VP-
PMLCs (light grey color) and 2VP-PMLCs (dark grey color), respectively, for 24h. The viral 
protein concentration was 0.1 mg/ml and the ratio of particle to cell was 100:1. Two molecular 




Altogether, BMDCs co-cultured with a ratio of 20 PMLC/cell for 24h, resulted in an 
average viability of 80%, and the viability decreased to 70% with a ratio of 100 PMLC/cell, 
which is similar to prior reports [107]. These results showed that VP-PMLC could be developed 
as a safe vaccine delivery vehicle for vaccine delivery systems. 
4.3.2 Release profile through confocal laser scanning microscope (CLSM) 
Dendritic cells are able to take up microparticles through either phagocytosis or 
macropinocytosis [123]. In order to understand how efficient BMDCs would uptake the particles, 
as well as the influence of the MW of polymer shells on uptake, we designed a set of 





fluorescently labeled reagents were used. The encapsulation procedures were the same as regular 
particles, as described above.  
Due to the electronic interaction between viral protein and polyelectrolytes, we 
hypothesize that silica beads that are similar in size to the viral protein can be used to mimic viral 
protein release. Therefore, we replaced SV40 VP1 with 20 nm diameter Cy5-labeled silica beads. 
The 2nd layer of dextran was switched to fluorescent dextran, with MW of either 500 kDa, 
denoted as (DS-F)H, or 10 kDa, denoted as (DS-F)L. The surface charge of each material was 
measured by Malvern Zetasizer Nano series and the results are shown in Table 3.  
 
Table 3. The surface charge of assembly materials 
Surface Charge CaCO3 Silica bead (PLARG)H (PLARG)L (DS)H (DS)L (DS-F)H (DS-F)L 
Mean (mV) -24.83 -45.53 24.47 32.83 -29.53 -9.47 -22.27 -10.40 
Standard deviation 0.86 1.85 10.43 6.29 10.56 6.36 4.47 5.37 
 
 
The differences between the normal and fluorescent particles are the fluorescent silica 
beads, as well as the fluorescent dextran in the 2nd layer. As can been seen in Table 3, the surface 
charge of low MW of fluorescent-dextran showed less negative charge than high MW of 
fluorescent-dextran, which showed the same trend as regular dextran polyelectrolyte. The surface 
charge of silica beads in pH 6.0, 0.5M NaCl is around -45 ± 0.86mV, while the SV40 VP1 viral 
protein is around -4.5 ± 4mV. The successful of encapsulation were confirmed by ξ-potential 











Figure 19 shows that the less negatively charged DS, like (DS)L and (DS-F)L also have 
less particles charged on the surface. However, the addition of silica beads in different layers, 
either in the 1st layer, Si-PMLC, or both in the 1st and 3rd layers, 2Si-PMLC, does not show a 
significant difference from the surface charge analysis. Overall, the pattern seen with the 
potential shows the success of the encapsulation by alternatively applying positively and 









Figure 20. SEM images of CaCO3 microparticles fabricated with fluorescent silica beads with 
high MW of polymer electrolytes. Scale bar, 1 µm. 
 
 
Before core removal, the (Si-PMLC)H were dried overnight and imaged in a dry state. For 
(Si-PMLC)H, the SEM images shown in Figure 20 additionally provides evidence of the success 
of encapsulation. The porous structure and the size of the particles are the same as normal 
PMLCs. Similar behavior was observed with other particles such as (Si-PMLC)H, (Si-PMLC)L, 
(2Si-PMLC)H and (2Si-PMLC)L as well. Together, the ξ-potential (Figure 19) and the SEM 







Figure 21. Fluorescent particles were fabricated by encapsulation of 20 nm Cy5-labeled silica 
beads with DS/PLARG polyelectrolytes. The fluorescent shell was formed by Alexa Fluor 488 
labeled DS located in 2nd layer. Confocal laser scanning microscope images were applied before 
core removal on (a) (Si-PMLC)H, (b) (Si-PMLC)L, (c) (2Si-PMLC)H and (d) (2Si-PMLC)L, 
respectively. As for the number denotation, (a1) both PMLC encapsulated fluorescent silica 
beads (red fluorescence), as well as fluorescent DS (green fluorescence), were represented, (a2) 
the red fluorescence showed the distribution of DS in 2nd layer; (a3) the green fluorescence 
indicated the 20nm silica beads, while (a4) whole particles without fluorescence were presented. 
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After the fluorescent Si-PMLCs were fabricated, confocal laser scanning microscope was 
used to study their intracellular distribution. The effect of different MW of polymers and 
different locations of silica beads were studied. The fluorescent silica beads were in 20 nm in 
diameter, used to mimic the SV40 VP1 viral protein. The 500 kDa and 10 kDa fluorescent DS 
was served as high and low MW of polyelectrolytes at the 2nd layer, respectively. Volodkin et al. 
reported that the average pore size of CaCO3 particles ranging from 3 to 15 µm in diameter is 
around 25 nm [103]. The diameter of DS with MW 2,000 kDa is ~56 nm, and the diameter was 
~3.4 nm with 4 kDa Dextran [172].  
Comparing Figure (21a) to (21b) and Figure (21c) to (21d), the core-shell structure is 
only partially displayed in high MW polyelectrolyte pairs. However, most of the high MW and 
all of the low MW of capsules are able to penetrate to the center of core. A similar conclusion 
can also be drawn from the fluorescence intensity data. From Figure (21a), we further found that 
the polyelectrolyte shell is ~ 400 nm. 
Figure (21a3) and (21b3) show that the fluorescent intensity is a solid circular image, 
which indicates an even distribution and suggests that the penetration phenomenon was seen in 
Si-PMLC. When applied on 2Si-PMLC, shown as Figure (21c3) and (21d3), the distribution of 
silica beads is more spread and gathered on the shell. This suggests that 2Si-PMLC facilitates 
localization of viral protein onto the shell and could be used for instant release. 
After characterizing fluorescent microparticles, experiments were conducted using DC2.4 







Figure 22. Time line for the in vitro release profile experiment using the DC2.4 cell line. 
 
 
DC2.4 dendritic cells were co-incubated with different capsules, such as (Si-PMLC)H, 
(Si-PMLC)C, (Si-PMLC)L, (2Si-PMLC)H and (2Si-PMLC)L. Cells were collected, fixed, and then 
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Figure 23. In vitro interaction between DC2.4 dendritic cells and Si-PMLCs. Confocal laser 
scanning microscope images were used to determine microparticle release profile co-incubated 
with (a) (Si-PMLC)H, (b) (Si-PMLC)C, as well as (c) (Si-PMLC)L, at 37
oC in 5% CO2 humidified 
environment for 4h. (a1) the red fluorescence shows Alexa Fluor 680 labeled DS; (a2) green 
fluorescence indicates 20nm Cy5-labeled silica beads; (a3) both PMLC encapsulated fluorescent 
silica beads, as well as fluorescent DS, are presented. A close-up image of the fluorescent 
intensity with (Si-PMLC)H and (Si-PMLC)L is shown in is shown in Figure (d) and Figure (e), 
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DC2.4 dendritic cells were first seed in a two-well chamber slide, and then co-incubated 
with (Si-PMLC)H, (Si-PMLC)C and (Si-PMLC)L particles. The fluorescence release profile was 
studied using CLSM. Figure 23 shows that most of the particles were engulfed by DC2.4 
dendritic cells within 4h. The fluorescent intensities in Figures (23d) and (23e) are different, and 
show that low MW polyelectrolytes of capsules are able to break into small pieces within 4h. 
However, this was not observed with high MW polyelectrolytes. The core-shell structure was 
also found in Figure (23d), which shows the core-shell structure on (Si-PMLC)H clearly even 
after the core removal. 
A potential limitation of this in vitro experiment is that the culture medium has to be 
changed every other day, leading to removal of microparticles from the culture. Since most of 
particles were engulfed within 4h (Figure 23), this might not be a problem and suggest that the 









Figure 24. In vitro interaction between DC2.4 dendritic cells and Si-PMLCs. Confocal laser 
scanning microscope images were used to determine microparticle release profile co-incubated 
with (Si-PMLC)H, (Si-PMLC)C, (Si-PMLC)L, (2Si-PMLC)H, as well as (2Si-PMLC)L, at 37
oC in 
5% CO2 humidified environment for 24h, 48h and 72h, respectively using a two-well chamber 
slide. Red fluorescence shows the Alexa Fluor 680 labeled DS, green fluorescence indicates 
20nm Cy5-labeled silica beads, while the yellow color showed the combination of red and green. 
The yellow arrow indicates area with green fluorescence alone. Scale bar, 10 µm. 
 
 
Longer duration experiments were designed to investigate the release profile. DC2.4 
dendritic cells were co-incubated with (Si-PMLC)H, (Si-PMLC)C, (Si-PMLC)L, (2Si-PMLC)H, as 
well as (2Si-PMLC)L, for 24h, 48h and 72h, respectively. The fresh culture medium was 
replaced on day 2. Cells were then fixed using 4% PFA and studied using CLSM.  
Figure 24 confirms that most of the microparticles were engulfed by DC2.4 dendritic 
cells. In row 1, after co-culturing for 24h, the leakage of silica beads are found in (Si-PMLC)C, 
(Si-PMLC)L and (2Si-PMLC)L (indicated by the yellow arrow). The green fluorescence 
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illustrates the location of silica beads, after the combination of red and green, the green color in 
the Figure also presents the existence of silica bead alone. Therefore, we found that the silica 
beads encapsulated by low MW of polymers, as well as the composite MW of polymers, were 
able to release within 24h. In row 2, more green color was found in (Si-PMLC)C, (Si-PMLC)L 
and (2Si-PMLC)L, meaning that more silica beads were released by 48h. However, for high MW 
of capsules, the images of (Si-PMLC)H and (2Si-PMLC)H are still more yellow and red, meaning 
the silica beads and the DS are still in the same location inside the cells.  
In row 3, the images show more red and green color separately; the green color is even 
present outside the red color, meaning the silica beads are no longer inside the shells and have 
leaked out. Surprisingly, at 72h, with (Si-PMLC)H, the red color is still very solid, and the shell 
does not appear to be broken like the low MW capsule. The same conclusions can be made from 
(Si-PMLC)C and (2Si-PMLC)H particles.  
In this experiment, by encapsulating silica beads in different locations, such as (Si-
PMLC)H vs. (2Si-PMLC)H and  (Si-PMLC)L vs. (2Si-PMLC)L, no significant differences in the 
release profiles were observed. This suggests that the factors controlling the leakage of 20 nm 
particles from PLARG/DS shell are related to the shell structure than the location. 
Altogether, as for the release profile of Si-PMLCs, we found that the silica beads 
assembled by low MW and composite MW of capsules were able to leak out within 24h; 
however, it took 72h for silica beads encapsulated by high MW of polymers to release, shown in 
Figure 25. So, with 2.5 layered PLARG/DS shell, silica beads could be released during 24-72h. 
Moreover, low MW capsules tend to break down easily, while the high MW capsules still retain 









Figure 25. Scheme to summary the release activity through the overall Si-PMLC behavior 
 
 
4.3.3 Stimulation and maturation of BMDC 
Immature dendritic cells circulate throughout the body, and look for foreign proteins. 
Once they engage foreign proteins they mature through uptake, process and present antigens to 
the cell surface, and also release signals to stimulate adaptive immunity that leads to 
development of memorized antibodies [5, 182]. We investigated the efficiency of immune 
response induction and dendritic cell maturation resulting from co-culturing dendritic cells with 
VP-PMLCs using flow cytometry.  
We previously demonstrated that PMLCs could be engulfed by dendritic cells in vitro. In 
order to successfully prime naïve T cells to generate antibodies, multiple molecule signals are 
required. A primary signal is the binding of cognate antigen in MHC-restricted manner to an 
antigen receptor expressed by T and B lymphocytes. Multiple secondary signals involve the 
engagement of co-stimulatory molecules expressed by T and B lymphocytes with their respective 
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ligands [116]. The co-stimulatory surface markers that we profiled are CD40 and CD86 on 
BMDCs.  
CD40 belongs to the tumor necrosis factor receptor family and is expressed by B cells, 
dendritic cells, macrophages and basal epithelial cells under inflammatory conditions [183, 184]. 
CD40 signaling induces dendritic cells to mature and achieve all of the necessary characteristics 
to effectively trigger T-cell activation and differentiation by engaging the surface of dendritic 
cells to promote cytokine production, induce co-stimulatory molecules and facilitate cross-
presentation of antigen [185, 186]. Therefore, CD40 plays an important role in the initiation and 
progression of cellular and humoral adaptive immunity.  
CD86 belongs to the CD28/B7 family and is expressed by monocytes, activated B cells 
and dendritic cells. The expression of CD86 presents one of the most important T‐cell co‐
stimulatory molecules and plays a major role in the activation of T cells, leading to their 
proliferation and cytokine production [187, 188]. These immune molecules can also be affected 
by the addition of an adjuvant, substances that enhance immunogenicity of antigens. With the 
addition of adjuvant, the antigen-adjuvant particles are capable of inducing a stronger immune 
response [38, 72, 88, 94].  Moreover, different adjuvants would lead to different immune 
responses, and the co-stimulatory molecule upregulation levels might also show differences 
[189]. Therefore, different adjuvants were prepared in our study. The method of stimulating 
surface markers was as described in the materials and methods section. A brief time line of the 







Figure 26. Time line for the in vitro immune response experiment 
 
 
In this experiment, we aimed to investigate the efficiency of BMDC stimulation by 
different antigens in vitro in response to viral protein, polymer microparticles, and viral protein 
capsules. As negative and positive controls, we co-incubated BMDCs with plain growth medium 
or LPS, respectively. Figure 27 (a1) and (b1) show that after 24h co-culture, more than 80% of 
BMDCs were still alive. The levels of CD11c (Figure 27a2. and 27b2) which suggests the 
presence of mature BMDCs were used to gate cells. Figure (27b3) and (27b4) further show the 
levels of CD40 and CD86 upon stimulation which show that BMDCs can be activated by LPS.   
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Figure 27. Activation marker expression by BMDCs was observed with negative and positive 
controls. Primary BMDCs were generated from C57BL/6 mice. After 6 days of culture from 
mice bone marrow cells and further 24h treatment, the maturation level was detected by flow 
cytometry analysis. (a) Without any treatment, negative control. (b) BMDC co-incubated with 
1000 ng/ml LPS, positive control. (a1), (a2), (b1), (b2) Live BMDCs were selected based on the 
distribution of FSC-SSC and the expression of CD11c. (b3), (b4) Flow cytometry analysis of 
BMDC maturation was induced by LPS. The gray color presents the stimulated levels of CD40 
and Cd86 on negative control. One representative experiment from three independent 
experiments with similar results is shown. 
 
 
The SV40 VP1 viral protein was co-incubated with freshly harvested BMDCs at different 
concentrations (10 μg/ml, 50 μg/ml and 100 μg/ml). After intercellular staining, changes in the 
expression of CD40 and CD86 were used to evaluate the extent of BMDC stimulation. Figure 28 
shows that after being gated by CD11c+, the CD40 and CD86 levels suggest that after 24h 


















































Compared to Figure 28, (a2) and (a3), the CD40 upregulation level on 10μg/ml and 
50μg/ml is similar. The same conclusion can be made based on the stimulation of CD86 
stimulation, Figure 28, (c2) and (c3). The mean fluorescent intensity of CD40 and CD86, shown 
as Figure (28b) and (28d), also indicate that compared to the 100 μg/ml, the stimulation level of 
viral protein concentration with 10 μg/ml and 50 μg/ml is much lower. However, when the viral 
protein concentration went up to 100 μg/ml, shown as Figure 28, (a1) and (c1), the stimulation 
level is comparable to the one co-incubated with LPS, shown as Figure 27, (b3) and (b4). 
 
 
Figure 28. In vitro interaction between BMDCs and SV40 VP1 viral protein was analyzed by 
flow cytometry. Freshly isolated BMDCs were co-incubated with viral protein in different 
concentrations, 100μg/ml (a1, c1), 50μg/ml (a2, c2) and 10μg/ml (a3, c3) for 24h. Cells were 
then stained with surface markers- CD11c, CD40 and CD86. Figure (a1), (a2) and (a3) show the 
CD40 level, gated by CD11c+, while the gray color indicates the negative control. Figure (b) 
shows their mean fluorescence intensities individually. Similarly, Figure (c1), (c2) and (c3) 
present the CD86 level, gated by CD11c+, while Figure (d) indicates their mean fluorescent 
intensity, respectively. One representative experiment from three independent experiments with 
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Figure 29. In vitro interaction between BMDCs and either PMLCs or VP-PMLCs was analyzed 
by flow cytometry. Freshly isolated BMDCs were co-incubated with different capsules at a 
capsule to cell ratio of 20:1 for 24h. Cells were then stained with surface markers- CD11c, CD40 
and CD86. Figures show the expression of CD40 in different conditions after being gated by 
CD11c+ expression. The histogram and mean fluorescent intensity of CD40 upregulation level 
are showed, respectively by co-incubated mice BMDCs with ((a) and (b) high MW of PMLCs, 
((c) and (d)) composite MW of PMLCs and ((e) and (f)) low MW of PMLCs. The gray color 
indicated the stimulated level of CD40 on negative control. Different antigen capsules were 
performed by encapsulating different MW of polymers showed in each row. From left to right, 
the investigation went by PMLC alone, VP-PMLCs, as well as 2VP-PMLC, indicated as 1, 2 and 
3, respectively. One representative experiment from three independent experiments with similar 
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CD40 is a co-stimulatory molecule belonging to the tumor necrosis factor superfamily 
and is essential in activation of dendritic cells. In order to study the immune response induced by 
viral protein capsules, BMDCs were co-incubated with either capsules or viral protein capsules 
for 24h, and the expression of CD40 detected by flow cytometry. Figure (29a) and (29b) 
represent the CD40 upregulation level and the mean fluorescent intensity of CD11c+ gated 
BMDCs, which were co-incubated with high MW of PMLCs, denoted as (PMLC)H. The 
numbers, 1, 2 and 3, indicate the capsules alone, viral protein capsules and viral protein capsules 
with two-layer encapsulation of viral protein, respectively. Figure (b) represents the PMLCs 
composed by composite MW of polymer, denoted as (PMLC)C. Figure (c) represents the PMLCs 
composed by low MW of polymer, denoted as (PMLC)L. The gray color shown in Figure (29a), 
(29c) and (29e) illustrates the CD40 level of negative control. 
The influence of the maturation level on mice BMDCs with the addition of viral protein 
and its distribution within the capsules is discussed below. In Figure 29, row a, (a1) represents 
the CD40 signal after BMDCs co-incubated with (PMLC)H, compared to the negative control, 
the gray curve, the curve is shifted a little to the right. When compared to Figure 29 (a2), the 
expression of CD40 is higher for (VP-PMLC)H, suggesting that the combination of viral protein 
and capsules was able to stimulate stronger immunity. In this experiment, the capsule to cell ratio 
was set at 20:1 with a viral protein concentration of 10μg/ml. Figure 28 (a3) shows that BMDCs 
co-incubated with 10μg/ml viral protein alone was barely able to activate DCs. However, the 
combination of viral protein with the adjuvant stimulates higher immune response, based on 
CD40 expression. More evidence for higher stimulation levels of CD40 expression on 
encapsulation form was provided by Figure (29c), (29d), (29e) and (29f). These results show that 





Comparing Figure 29 (a2) to (a3), we found that, (2VP-PMLC)H elicited a higher 
immune response than (VP-PMLC)H, suggesting that the viral protein located in the outer layer 
might be more accessible to DCs. Interestingly, Figure 24 shows that the silica beads were not 
released from high MW of capsules until 72h co-incubation; however, in Figure (29a) we find 
that within 24h co-incubation, the viral protein is released and induced the immune response. 
This phenomenon is likely due to the porous structure of the PMLCs. Though the shell was not 
able to break down within 24h, the enzyme in the medium could access the viral protein through 
the pores. This is similar to the observations made by Stefaan et al [41]. This likely explains the 
induction of a stronger immune response within 24h. Figure (29b), (29d) and (29f), represent the 
mean fluorescence intensity per cell under the different conditions. These results show that the 
viral protein capsules induced a higher mean fluorescence intensity than the capsules itself, 
which further confirmed that the combination of antigen and adjuvants stimulate a stronger 
immune response. 
When comparing Figure (29a), (29c) and (29e), each column presents the same 
observation that the capsules encapsulated by composite MW polymers displays the lowest 
stimulation level, while capsules composed of low MW polymers induces the highest immune 
response. Therefore, we found that low MW of PLARG/DS adjuvant itself was capable of 
inducing higher immunity. 
CD86 is another co-stimulatory molecule that determines DC maturation, as well as the 
capability for triggering T cell activation to activate the adaptive immune system. Using the 








Figure 30. In vitro interaction between BMDCs and either PMLCs or VP-PMLCs was analyzed 
by flow cytometry. Freshly isolated BMDCs were co-incubated with different capsules by the 
capsule to cell ratio of 20 for 24h. Cells were then stained with surface markers- CD11c, CD40 
and CD86. After being gated by CD11c+, the expression of CD86 in different conditions is 
shown. Figure (a) and (b) show CD86 upregulation level with (PMLC)H, represented by the 
histogram and its mean fluorescent intensity, respectively. Similarly, Figure (c) and (d) show 
BMDCs co-incubated with (PMLC)C while Figure (e) and (f) show the interaction between 
BMDCs and (PMLC)L. The gray color indicates the stimulated level of CD86 relative to the 
negative control. The conditions shown from left to right are: PMLC alone, VP-PMLCs, 2VP-
PMLC, indicated as 1, 2 and 3. One representative experiment from three independent 
experiments with similar results is shown. *p < 0.05, **p < 0.01. 
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CD86, a protein expressed on APCs, provides co-stimulatory signals necessary for T cell 
activation and survival. In order to know how efficiently the viral protein capsules promote 
BMDC maturation, cells were co-incubated with either capsules or viral protein capsules for 24h, 
and the expression of CD86 was detected by flow cytometry. Comparing Figure 30 (a1), (a2) and 
(a3), the expression of CD86 on mice BMDCs, gated by CD11c+ is slightly higher for (2VP-
PMLC)H and (VP-PMLC)H compared to (PMLC)H. Though the differences are not significant, 
the curve is different from the PMLCs alone. In Figure (30b), the data indicates that the mean 
fluorescent intensity does not increase with viral protein capsules, though the curve does shift to 
the right more, meaning the viral protein capsules might have induced higher activation in some 
cells; however, others cells still had a low activation level. Observations from Figure 30, (c), (d), 
(e) and (f) further confirms that the viral protein capsules shows higher CD86 stimulation but not 
compared to CD40 upregulation.   
Taking the encapsulation MW of polymers into consideration, the increase in CD86 
expression (Figure 30) shows a similar trend to the expression of CD40 on mice BMDCs, gated 
by CD11c+, (Figure 29). The (PMLC)L capsule was able to elicit stronger immune response 
compared to the (PMLC)H and (PMLC)C, which again confirmed that low MW of PLARG/DS 
pair could induce higher BMDC maturation and enhance immune responses in vitro. 
4.4 Summary 
In this chapter we studied the cytotoxicity, release profile and the immune response of 
BMDC and DC2.4 dendritic cells to different co-culture conditions in vitro. We found that 
BMDCs co-cultured for 24h with microparticles at a ratio of 20:1 had an overall viability of 





considering the different MWs of capsules, low MW capsules had less toxicity (or higher 
viability) than the other conditions. 
We used fluorescent silica beads to mimic the viral protein, and fluorescent dextran to 
replace original material, and visually investigated the particle structure using CLSM. We found 
that all capsules were engulfed by DC2.4 dendritic cells within 4h. We observed that silica beads 
leaked out within 4h for low MW Si-PMLCs; however, leakage of silica beads was observed 
only after 48h for high MW Si-PMLCs. Moreover, localizing silica beads in the outer layer did 
not lead to early release, suggesting that the MW of capsules is more important for release. 
BMDCs treated with VP-PMLCs showed that low MW capsules and viral proteins 
located in outer layer were two factors that could efficiently induce an immune response, as seen 
from the expression of CD40 and CD86. This data also showed that the combination of antigen 






5. CELLULAR MECHANISMS ACTIVATED BY VP-PMLC: AN IN VITRO STUDY 
 
In Chapter 4, we demonstrated that VP-PMLCs upregulate the expression of the DC co-
stimulatory molecules CD40 and CD86. In this chapter we investigate in vitro the molecular 
mechanisms and signaling pathways engaged when VP-PMLCs activate the innate immune 
system.  
5.1 Introduction 
Activated DCs upregulate the production of a distinct panel of cytokines and co-
stimulatory molecules, which eventually leads to initiation of the adaptive immune response in 
the body [5]. Activation of inflammasome is one of the key intermediate steps initiated by 
activated DCs in response to harmful stimuli. Inflammasomes are multimeric protein complexes 
that assemble in the cytosol after sensing damage-associated molecular patterns or pathogen-
associated molecular patterns [190].  
Therefore, we investigated in vitro the cytokine secretion and inflammasome activation in 
BMDCs upon co-incubation PMLCs. Cytokines (TNF-α, IL-12 and IL-1β) in the cell culture 
supernatant after 24h incubation using ELISA assay kits. Chemical inhibitors were used to 
investigate the molecular mechanisms involved in up-regulation of cytokine production. 
5.2 Materials and methods 
BMDCs were isolated from C57BL/6 mice and cultured as described in Chapter 4.  
CA-074 methyl ester (CA-074 ME) and Latrunculin A (Lat. A) were purchased from 
Sigma Aldrich. Mouse IL-12 ELISA kits (mouse IL-12 ELISA kit) were purchased from Thermo 
Fisher Scientific. Tumor Necrosis Factor-α (TNF-α) assay kits (mouse TNF-α platinum ELISA 





Invitrogen. All cytokine assays were carried out following the manufacturer’s recommended 
protocols. 
Ultrapure water used for all experiments was obtained from a Millipore system with a 
specific resistance 18.2MΩ/cm. 
All experiments were carried out in triplicate. Mice BMDCs were seeded in 96-well flat 
bottom tissue culture plates at a cell density of ~105/well. For all treatment conditions, the ratio 
of PMLCs and VP-PMLCs to cells was 20:1, and the viral protein concentration was 100 μg/ml, 
50 μg/ml, or 10 μg/ml (denoted as VP-100, VP-50 and VP-10, respectively). Co-treated BMDCs 
were incubated at 37oC in 5% CO2 humidified environment for another 24h. For all cytokine 
assays, BMDCs culture supernatant was used as the negative control. For TNF-α and IL-12 
cytokine assays, supernatant from cells stimulated with 1000 ng/ml LPS was used as the positive 
control. For IL-1β assays, supernatant from cells stimulated with 10 ng/ml LPS was used as the 
positive control. 
For NLRP3 inflammasome activation studies, cathepsin B inhibitor, CA-074 Me, and 
actin polymerization inhibitor, Lat. A, were used.  BMDCs were exposed to either 50 μM of CA-
074 Me or 250 nM Lat prior to addition of particles and cells were incubated for 24h.  
5.3 Results 
5.3.1 Tumor Necrosis Factor-α (TNF-α) secretion 
TNF-α is a major pro-inflammatory cell signaling protein involved in early inflammatory 
events and is one of the major cytokines secreted during the acute phase response [136]. The 
production of TNF-α induces the expression of other inflammatory molecules, including IL-8 
[191], chemokines such as CCL3 (chemokine (C-C motif) ligand 3), CCL4, CCL2 [192], 





nitrogen intermediates [196]. TNF-α is produced mainly by activated macrophages, but it can be 
produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, 
eosinophils, and neurons. 
BMDCs were cultured 6 days, exposed to different concentrations of SV40 VP1 viral 
protein for 24h, and cytokine levels in the culture supernatant determined. Figure 31 shows that 
compared to LPS stimulation, BMDCs co-incubated with SV40 VP1 viral protein secreted TNF-
α only at the highest concentration of VP1 (100 μg/ml). At the lower concentrations, no 
significant TNF-α was detected in the supernatant.  
 
 
Figure 31. TNF-α secretion in BMDCs exposed to different concentrations (100 μg/ml, 50 μg/ml, 
or 10 μg/ml) of SV40 VP1 viral protein. LPS was used as a positive control, untreated cells were 
used as a negative control. *p < 0.05. 
 
 
The same experimental design was used to co-culture BMDCs with either PMLC, VP-
PMLC or 2VP-PMLC at a particle to cell ratio of 20:1 for 24h. Overall, compared to the negative 






death or phagocytosis was observed, these results suggest that PLARG/DS capsules are not able 
to induce TNF-α secretion due to their immunocompatibility[197] or thpossible because the 
capsules induce the expression of other cytokines. 
 
 
Figure 32. TNF-α secretion in BMDCs incubated with PMLCs (white color), VP-PMLCs (light 
grey color) and 2VP-PMLCs (dark grey color), respectively, for 24h. The ratio of particle to cell 
was 20:1. Two molecular weights of PLARG/DS polyelectrolyte pairs were used to encapsulate 
viral proteins and untreated cells were used as the negative control. 
 
 
5.3.2 Interleukin-12 (IL-12) secretion 
Interleukin 12 (IL-12) is a proinflammatory cytokine produced by phagocytic cells such 
as dendritic cells, macrophages, neutrophils, and human B-lymphoblastoids in response to 
antigenic stimulation. IL-12 is also known as a T cell-stimulating factor, and plays a major role 
in cellular immunity, notably by inducing lymphocytes to produce IFN-γ [135]. IL-12 signals 
through heterodimeric receptor complexes that contain IL-12 R β1 paired with IL-12 R β2 for the 





signaling pathway and phosphorylation of the transcription factors signal transducer and 
activator of transcription 1 (STAT1), STAT3, and STAT4.  
BMDCs were cultured 6 days, exposed to different concentrations of SV40 VP1 viral 
protein for 24h, and IL-12 levels in the culture supernatant determined. Untreated BMDCs were 
used as the negative control while exposure to 1000 ng/mL of LPS for 12h was used as the 
positive control. Compared to the LPS control, none of the viral protein samples significantly 
increased IL-12 levels (Figure 33).  
 
 
Figure 33. IL-12 secretion with different levels of \SV40 VP1 viral protein. LPS was used as the 
positive control, and untreated BMDCs were used as the negative control. *p < 0.05 
 
 
When BMDCs were co-cultured with either PMLC, VP-PMLC or 2VP-PMLC at a 20:1 
ratio of particles to cells for 24h, none of the tested capsules significantly induced IL-12 
secretion compared to the negative control (Figure 34). Moreover, no cell death or phagocytosis 










Figure 34. IL-12 secretion in BMDCs incubated with PMLCs (white color), VP-PMLCs (light 
grey color) and 2VP-PMLCs (dark grey color), respectively, for 24h. The ratio of particle to cell 
was 20:1. Two molecular weights of PLARG/DS polyelectrolyte pairs were used to encapsulate 
the viral protein. Untreated cells were used as the negative control. 
 
 
5.3.3 Interlukin-1β (IL-1β) Secretion  
Most particulate material are known to activate NLRP3, a lymphocyte activating factor 
mediating the acute phase inflammatory response [129, 131, 148, 199, 200]. The process of 
NLRP3 inflammasome activation involves a conformational change in NLRP3 into its active 
form, which then associates with its adaptor protein (apoptosis-associated speck-like protein) 
through pyrin domain interactions. This complex leads to the recruitment of pro-caspase-1 
through caspase activation and recruitment domain interactions [201]. Pro-caspase-1 is then 





the active cytokine IL-1β [202], which is capable of differentiating naïve T-cells to TH17 cells. 
Therefore, the activation of NLRP3 leads to the processing and secretion of IL-1β. LPS, even at 
low concentrations, can prime dendritic cells to up-regulate pro-IL-1β [132]; however, mature 
IL-1β secretion is not observed. Therefore, a second stimulation is likely required for IL-1β 
production.  
In this work, BMDCs were co-incubated with PMLC or VP-PMLC either alone or in 
combination with low dose of LPS (10 ng/ml) at different time points. The experimental design 
is shown in Figure 35. 
 
 
Figure 35. Time line for the in vitro stimulation of BMDCs with capsules for IL-1β production 
 
 
High MW of PMLCs and VP-PMLCs were co-incubated with BMDCs at a particle/cell 
ratio of 20:1 in 96-well plates. LPS (10 ng/ml) was added to all conditions at different time 
points (Figure 35). At 24h after addition of the particles, supernatants were collected and used to 
assay for IL-1β. 
Figure 36 shows that BMDCs that received LPS 8h ahead of the capsule addition show 






















relatively similar. Moreover, when considering the effect of VP addition VP, the levels of IL-1β 
for VP-PMLC (grey color) was higher than PMLC (white color) at all those time points. LPS 
alone does not elicit a significant induction of IL-1β, which is consistent with previous reports 
[131]; however, IL-1β is detectable with either co-incubation of PMLC or VP-PMLC alone.  
 
 
Figure 36. Particle-induced IL-1β secretion in BMDCs incubated with high MW PLARG/DS 
polyelectrolyte PMLCs (white color) and VP-PMLCs (grey color), respectively. The ratio of 




The same experimental design was used to co-incubate BMDCs with composite MW 
PMLC and VP-PMLC with composite MW (Figure 37) and low MW (Figure 38) capsules. 
Figure 37 shows the highest IL-1β secretion is observed when LPS added 8h prior to particle 
addition, and at all four time points higher levels of IL-1β were detected with VP-PMLC 








Figure 37. Particle-induced IL-1β secretion in BMDCs incubated with composite MW 
PLARG/DS polyelectrolyte PMLCs (white color) and VP-PMLCs (grey color), respectively. The 
ratio of particle to cell was 20:1, and LPS concentration was 10 ng/ml. Untreated cells were used 
as the negative control. 
 
 
Figure 38 shows enhancement of IL-1β secretion by low MW PMLC capsules was 
similar to the observations with high MW (Figure 36) and composite MW (Figure 37) particles. 
Comparing Figures 36 - 38, the composite MW particles were the most potent in inducing IL-1β, 
secretion, followed by high MW and low MW particles. Moreover, these studies also showed 
that PLARG/DS microparticles alone could enhance IL-1β secretion, which is in contrast to other 







Figure 38. IL-1β secretion in BMDCs incubated with low MW PLARG/DS polyelectrolyte 
PMLCs (white color) and VP-PMLCs (grey color), respectively. The ratio of particle to cell was 
20:1. The LPS concentration was 10 ng/ml. Untreated cells were used as the negative control. 
 
 
Figure 39 shows the effect of LPS alone or with soluble antigen (VP1) at different time 
points on IL-1β secretion. The data show that LPS alone cannot increase IL-1β secretion at any 
time point. Moreover, even with the addition of LPS, VP1 did not significantly increase IL-1β 
release. However, Figures 36-38 clearly show that VP-PMLC is capable of increasing IL-1β 
secretion compared to PMLC. Therefore, these findings suggest that the uptake routes of soluble 
and particulate antigens are different, and inflammasome activation leading to IL-1β release 








Figure 39. IL-1β secretion in BMDCs incubated either with LPS alone, soluble antigen (SV40 
VP1 viral protein) alone, or VP1 together with the addition of LPS at 16h and 8h ahead, at the 
same time or 8h later, respectively. The VP concentration was 0.1 mg/ml, and LPS concentration 
was 10 ng/ml. Untreated cells were used as negative control.  
 
 
Activation of the NLRP3 inflammasome by microparticles is dependent on particle 
uptake, lysosomal acidification, and cathepsin B activity [131]. For microparticles with the size 
around 10μm, actin polymerization has been proposed to be involved in particle uptake  [129]. 
Therefore, we studied the effect of the cathepsin B activity and actin polymerization using 
chemical inhibitors. 
BMDCs were co-incubated either with (PMLC)C or (VP-PMLC)C. LPS was added 8h 
before addition of the particles and incubated for additional 24h. Figure 40 (first and second 
group of bars) shows the increase in IL-1β secretion in BMDCs co-cultured with PMLCs and the 
effect of LPS priming, respectively. With the addition of a cathepsin B inhibitor, CA-074 Me 
(Figure 40, group 3), IL-1β cytokine was essentially abolished. However, addition of an actin 





secretion, and was comparable to that observed with the particles and LPS altogether (Figure 40, 
group 2).  
These results suggest that cathepsin B activity, but not actin polymerization,  is required 
for activation of the NLRP3 inflammasome-signaling complex and IL-1β secretion in BMDCs 
co-cultured with PMLCs.  
 
 
Figure 40. Effect of cathepsin B inhibitor CA-074 Me and actin polymerization inhibitor Lat. A 
on IL-1β secretion. BMDCs were co-treated with (PMLC)C and LPS at a particle to cell ratio of 
20:1. The LPS concentration was 10 ng/ml, the CA-074 Me concentration was 50μM, and the 
Lat. A concentration was 250 nM. Untreated cells were used as the negative control. *p < 0.05, 




In this chapter, we investigated the effect of particles on cytokine release profiles using 
BMDCs in vitro. Changes in the secretion of TNF-α, IL-12 and IL-1β were investigated after 24h 
incubation. Only a high concentration of SV40 VP1 viral protein (0.1 mg/ml) induced an increase 







secretion was observed. Mice BMDCs co-incubated for 24h with any of the PMLCs at a 
particle/cell ratio of 20:1, did not lead to an increase in TNF-α secretion. Neither viral protein, 
PMLCs nor VP-PMLCs co-incubated with mice BMDCs induced a significant increase in the 
secretion of IL-12. These results suggest that TNF-α and IL-12 signaling may not be activated 
upon uptake of viral protein capsules in BMDCs. 
On the other hand, BMDCs co-incubated with either LPS and PMLC, LPS and VP-
PMLC, or PMLC alone, but not LPS alone or viral protein alone, resulted in increased IL-1β 
secretion. The highest IL-1β secretion was observed with the addition of LPS 8h prior to the 
particles. Cathepsin B activation is required for IL-1β secretion with 3μm microparticles, while 





6. CONCLUSIONS AND FUTURE WORK 
 
6.1 Conclusions 
 Recombinant SV40 viral protein VP1 was successfully expressed suing a baculovirus 
expression vector system in Sf9 insect cells and purified using affinity chromatography. VP1 has 
low toxicity in dendritic cells in vitro but also shows poor immunogenicity. A novel viral 
protein-based polymeric multilayer capsule serving as vaccine vehicle was developed. 
Biodegradable PLARG/DS polyelectrolyte pairs and SV40 VP1 viral protein were successfully 
assembled onto CaCO3 sacrificial porous microparticles through LbL deposition. The size range 
of particles formed varied from 1 to 4 μm in diameter.  
This study investigated two methods for particle formulation and the use of different 
molecular weights of PLARG/DS polyelectrolyte pairs. The highest viral protein encapsulation 
efficiency obtained was 63% using high molecular weight polyelectrolyte pairs with VP1 
deposited only in the 1st layer. However, based on the number of particles formed, the amount of 
viral protein was similar among all capsules. All VP-PMLCs demonstrated low toxicity in vitro. 
The porous structure of the capsule led to higher surface marker protein expression in dendritic 
cells vitro, with synergism between PLMCs and VP. We further show that the particles increased 
IL-1β secretion in dendritic cells and this required cathepsin B activity.  
Overall, VP-PMLCs, compared to VP1 alone or PMLCs alone, show lower cytotoxicity 
but higher co-stimulatory activity in vitro. When encapsulated using LbL technique, additional 
layer of VP1 are not important for activity; however, the MW of polyelectrolytes does influence 





Our results demonstrate that SV40 VP1-based polymeric multilayer capsules can elicit 
stronger immune response using viral protein. We further show that viral protein encapsulated 
with low MW polyelectrolytes is an attractive candidate for vaccine delivery. Further studies will 
focus on improving the protein encapsulation efficiency through different approaches of core 
synthesis and the in vitro signaling pathway. 
6.2 Future Work 
6.2.1 In vivo  studies using VP-PMLCs 
The work presented here demonstrates effectiveness of the VP-PMLCs in vitro using 
primary dendritic cells and cell lines. The next logical step is to test the effectiveness of VP-
PMLCs in mouse models. Since a wide range of immunological tools and reagents for 
characterization of innate and adaptive immune responses are available, it would be interesting to 
determine the effect of VP-PLMCs on different immune cells in vivo.   
6.2.2 Comprehensive investigation of cytokines and signaling pathways activated by 
VP-PMLCs 
In Chapter 5, we identified that IL-1β, but not TNF-α and IL-12, were upregulated in 
dendritic cells in vitro. To understand the cytokines and signaling pathways activated by VP-
PMLCs, comprehensive profiling of inflammatory cytokines and chemokines must be carried 
out. While our work showed the requirement for cathepsin B activity in the upregulation of IL-
1β, the role of actin polymerization was not verified for 3 μm particles. This would be a logical 
next step in delineating the mechanisms underlying increased IL-1β expression with VP-PMLCs. 
Due to the high surface curvature on PLARG/DS capsule, different mechanisms of phagocytosis 
such as lipid draft internalization could be possible. These additional mechanisms could be 





6.2.3 Application to mucosal delivery  
Vaccination through the parenteral route shows the fastest and highest bioactivity. 
However, inconvenience to patients and noncompliance, there is a need for other vaccine 
delivery routes, such as mucosal delivery. The most efficient way to elicit mucosal immunity is 
through the administration of vaccines onto the mucosal surfaces [203]. The mucosal membrane, 
which is vulnerable to infection, is a strong candidate for vaccine delivery not only due to its 
convenience, but also due to the large surface area at multiple locations (oral, nasal, rectal or 
vaginal). Nevertheless, there are difficulties associated with measuring the dose that actually 
enters the body and elucidating complicated mucosal immune responses, including T cell 
proliferation. The development of mucosal vaccines is still in its infancy as the low 
bioavailability of soluble antigens in circulation is low. The promising results from this work can 
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APPENDIX A FLUORESCENT-PMLC ENCAPSULATION 
 
Chitosan is a nontoxic linear polysaccharide composed of β-1,4-linked D-glucosamine. 
It’s a naturally occurring polymer, derived from the deacetylation of chitin which was found in 
the exoskeletons of crustaceans and insects. Due to its biodegradable and biocompatible 
properties, it’s commonly used for pharmaceutical and medical applications.  
Additionally, while considering the suitable polyelectrolytes for surface modification, 
chitosan is always evident. Because of its ability to open tight junctions and adhere on the 
mucosal surface [28], the weak positive charge also makes it capable of being a polycation. 
However, it could be dissolved in water only when the pH value is lower than 4. Therefore, it 
could not be used in our system, because the low pH surrounding resulted in the core 
decomposed simultaneously, scanning electron microscopy image was shown in Figure 41. From 
the SEM image, the structure is not microsphere as we expected and even the morphology is 
unlike other PMLCs after core removal. 
 
 
Figure 41. FE-SEM image of the PMLCs encapsulated BSA with 3 bilayers and followed by 






APPENDIX B BOVINE SERUM ALBUMIN ENCAPSULATION 
 
Bovine Serum Albumin (BSA), with MW of 66.5 kDa, pI value of 4.7 and 7 nm in 
diameter, was first used as an model antigen temporarily, serving for primary verification and 
study of the PMLCs. 
To study the structure of the particles, BSA was labeled with fluorescent isothiocyanate 
(FITC). FITC was first dissolved in 0.1 M carbonate-bicarbonate buffer, and FITC-BSA was 
bound at a molar ratio of 10:1, after incubating for 2 hours at room temperature, the solution was 
then collected by flowing through the Sephadex G-25M column gel bed.  
Confocal Laser Scanning Microscopy was used to investigate the distribution of 
encapsulation. One drop of well-suspended FITC-PMLCs was spread and placed on a glass slide 
covered by #1.5 coverslip. Confocal micrographs were taken with Olympus FV1000 Confocal 
Microscope and equipped with a 100x oil immersion objective with a numerical aperture of 1.4. 
The excitation wavelength was 488nm for detecting FITC labeled protein and 633 nm for 
detecting Alexa Fluor® 647. 
In order to verify the adsorption mechanism, the FITC-BSA was encapsulated to PMLCs. 
From the CLSM images, shown in Figure 42, the profile presents higher fluorescence intensity 
from the edge than from the center. Meanwhile, it reveals that the FITC-BSA with a 
hydrodynamic diameter of about 12nm is able to penetrate through porous structure into the 







Figure 42. CLSM images of PMLCs encapsulated FITC-BSA with 2.5 bilayers (a, b), and (c) is 
the fluorescence profile for image (b). 
 
 
The effect of the size of protein on encapsulation efficiency was also investigated. Bovine 
serum albumin with 7 nm in diameter was fabricated into PMLC with the same approach as (VP-
PMLC)H. The encapsulation efficiency was 50%, which was lower than that of (VP-PMLC)H. A 
possible reason could be the limited diffusion of larger biomacromolecules through the capsule 
[204]. Therefore, viral protein with a larger size appears to be a better candidate for PMLC 
encapsulation. 
a b c 
